OA17169A

OA17169A - Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation.

Info

Publication number: OA17169A
Application number: OA1201400285
Authority: OA
Inventors: Brian Metcalf; Chihyuan Chuang; Jeffrey Warrington; Kumar PAULVANNAN; Matthew P. Jacobson; Lan HUA; Bradley Morgan
Original assignee: Global Blood Therapeutics; Cytokinetics, Inc.; The Regents Of The University Of California
Priority date: 2011-12-28
Filing date: 2012-12-28
Publication date: 2016-04-05

Abstract

Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

Description

FIELD OF THE INVENTION

The présent invention generally relates to substîtuted benzaldehydes and dérivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their préparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders médiate by hemoglobin and disorders that would benefit from încreased tissue oxygénation.

BACKGROUND OF THE INVENTION

Hemoglobin (Hb) is a tetrameric protein in red blood cells that transports up to four oxygen molécules from the lungs to various tissues and organs throughout the body. Hemoglobin binds and releases oxygen through conformational changes, and is in the tense (T) state when it is unbound to oxygen and in the relaxed (R) state when it is bound to oxygen. The equilibrium between the two conformational states is under allosteric régulation. Natural compounds such as 2,3-bisphosphoglycerate (2,3-BPG), protons, and carbon dioxide stabilize hemoglobin in its de-oxygenated T state, while oxygen stabilizes hemoglobin in its oxygenated R state. Other relaxed R states hâve also been found, however their rôle in allosteric régulation has not been fully elucidated.

Sickle cell disease is a prévalent disease particularly among those of African and Mediterranean descent. Sickle hemoglobin (HbS) contains a point mutation where gjutamic acid is replaced with valine, allowîng the T state to become susceptible to polymerization to give the HbS containing red blood cells their characteristic sickle shape. The sickled cells are also more rigid than normal red blood cells, and their lack of flexibility can lead to blockage of blood vessels. Certain synthetic aldéhydes hâve been found to shift the equilibrium from the polymer forming T state to the non-polymer forming R state (Nnamani et al. Chemistry & Biodiversity Vol. 5,2008 pp. 1762-1769) by acting as allosteric modulators to stabilize the R state through formation of a Schîff base with an amino group on hemoglobin.

US 7,160,910 discloses 2-furfuraldehydes and related compounds that are also allosteric modulators of hemoglobin. One particular compound 5-hydroxymethyl-2furfûraldehyde (5HMF) was found to be a potent hemoglobin modulator both in vitro and in vivo. Transgenic mice producing human HbS that were treated with 5HMF were found to hâve significantly improved survival times when exposed to extreme hypoxia (5% oxygen). Under these hypoxie conditions, the 5HMF treated mice were also found to hâve reduced amounts of hypoxia-induced sickled red blood cells as compared to the non-treated mice.

A need exists for therapeutics that can shift the equilibrium between the deoxygenated and oxygenated states of Hb to treat disorders that are mediated by Hb or by abnormal Hb such as HbS. A need also exists for therapeutics to treat disorders that would benefit from having Hb in the R state with an increased afiinity for oxygen. Such therapeutics would hâve applications ranging, for example, from sensitizing hypoxie tumor cells that are résistant to standard radiotherapy or chemotherapy due to the low levels of oxygen in the cell, to treating pulmonary and hypertensive disorders, and to promoting wound healing.

BRIEF SUMMARY OF THE INVENTION

The présent invention provides, in one aspect, allosteric modulators of hemoglobin. In another aspect, provided are pharmaceutical compositions comprising the allosteric modulators disclosed herein. In otheraspects, provided are methods for treating disorders mediated by hemoglobin and methods for increasing tissue oxygénation for treating disorders that would benefit from increased oxygénation, such methods comprising administering the allosteric modulators disclosed herein to a subject in need thereof. In still other aspects, provided are methods for preparing the allosteric modulators disclosed herein. These and other embodiments ofthe invention are more fully described in the description that follows.

DETA1LED DESCRIPTION OF THE INVENTION

I. Définitions

As used herein, the below terms hâve the following meanings unless specified otherwise.

The abbreviations used herein are conventional, unless otherwise defined: aq = aqueous; Boc » t-butylcarboxy, (Boc)₂0 = di-/er/-butyl dicarbonate, °C = degrees celcïus, mCPBA = m-chloroperoxybenzoic acid, DCM = dichloromethane (CH2C12), DIBAL = diisobutylaluminum hydride, DMF = dimethyl formamide, EtOAc = ethyl acetate, g = gram, 2

H2 = hydrogen; H2O = water, HBr = hydrogen bromide; HCl = hydrogen chloride, HPLC = high pressure liquid chromatography, h = hour, LAH ·= lithium aluminum hydride (Li A1H4); MeCN = acetonitrile; MS = Mass Spectrum, m/z = mass to charge ratio, MHz = Mega Hertz, MeOH ·= méthanol, μΜ ~ micromolar, pL = microliter, mg = milligram, mM = millimolar, 5 mmol = millimole, mL ·= milliliter, min = minute, M ·= molar, Na2CO3 = sodium carbonate, ng ·= nanogram, N = Normal, NMR = nuclear magnetic résonance, Pd/C « palladium on carbon, rp reverse phase, sat - saturated, rt = room température, TEA « triethylamine, THF — tetrahydrofuran, TFA = trifluoroacetic acid, TLC = thin layer chromatography, and TMS = trimethylsilyl.

It is noted here that as used in this spécification and the appended daims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictâtes otherwise.

“Alkoxy” refers to -O(alkyl) where alkyl as defined herein. Représentative examples of alkoxy groups include methoxy, ethoxy, ί-butoxy, and the like.

“Alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, fully saturated aliphatic hydrocarijon radical having the number of carbon atoms designated. For example, “Ci.«alkyl” refers to a hydrocarbon radical straight or branched, containing from I to 8 carijon atoms that is derived by the removal ofone hydrogen atom from a single carbon atom of a parent alkane. Alkyl includes branched chain isomers of straight chain alkyl groups such as îsopropyl, t-butyl, isobutyl, sec-butyl, and the like. Représentative alkyl groups include straight and branched chain alkyl groups having I, 2,3,4,5,6,7,8,9,10,11 or 12 carbon atoms. Further représentative alkyl groups include straight and branched chain alkyl groups having 1,2,3,4,5,6,7 or 8 carbon atoms.

“Alkenyl” refers to a linear monovalent hydrocarbon radical or a branched monovalent hydrocarbon radical having the number of carbon atoms indicated in the prefix and containing at least one double bond, but no more than three double bonds. For example, Cî-galkenyl is meant to include, ethenyl, propenyl, 1,3-butadienyI and the like.

“Alkynyl” means a linear monovalent hydrocarbon radical or a branched monovalent hydrocarbon radical containing at least one triple bond and having the number of 30 carbon atoms indicated in the prefix. The term alkynyl” is also meant to include those alkyl groups having one triple bond and one double bond. For example, Cî-galkynyl is meant to include ethynyl, propynyl and the like.

The term “allosteric modulators refers to compounds that bind to hemoglobin to modulate its afïïnity for oxygen. In one group ofembodiments, the allosteric modulators act to stabilize or destabilize a particular hemoglobin conformation. In one group of embodiments, the modulators stabilize the relaxed R state. In other embodiments, the modulators destabilize the tense T state. In one group ofembodiments, the allosteric modulators can destabilize one conformation while stabilizing another. In some such embodiments, the modulators stabilize a relaxed R state and destabilize the tense T state. The modulators, in addition to modulating the afïïnity of hemoglobin for oxygen, may also confer additional properties to hemoglobin such as increasing its solubility. The présent disclosure ïs not intended to be limited to the mechanism by which the allosteric modulators interact with and regulate hemoglobin. In one group of embodiments, the allosteric modulators inhibit the polymerization of HbS and the sickling of red blood cells. In one group of embodiments, the binding of the allosteric modulators provided herein to hemoglobin can occur through covalent or non-covalent interactions. In one embodiment, the allosteric modulators react through its aldéhyde substituent with an amine group on a hemoglobin amino acid side chain to form a Schiffbase.

“Amino” refers to a monovalent radical -NH2.

“Aryl” by itself or as part of another substituent refers to a polyunsaturated, aromatic, hydrocarbon group containing from 6 to 14 carbon atoms, which can be a single ring or multiple rings (up to three rings) which are fiised together or linked covalently. Thus the phrase includes, but is not limited to, groups such as phenyl, bïphenyl, anthracenyl, naphthyl by way of example. Non-limiting examples of aryl groups include phenyl, 1-naphthyl, 2-naphthyl and 4-biphenyl.

“Bond” when used as an element in a Markush group means that the correspondîng 25 group does not exist, and the groups of both sides are directly linked.

“Cycloalkyl” refers to a saturated or parti al! y saturated cyclic group of from 3 to 14 carbon atoms and no ring heteroatoms and having a single ring or multiple rings including fused, bridged, and spiro ring Systems. The term “cycloalkyl” includes cycloalkenyl groups, a partially saturated cycloalkyl ring having at least one site of >C=C< ring unsaturation.

Examples of cycloalkyl groups include, for instance, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and cyclohexenyl. “Cu-.v’cycloalkyl” refers to cycloalkyl groups having u’ to v’ carbon atoms as ring members. “C_u-._V’cycloalkenyl” refers to cycloalkenyl groups having u’ to v* carbon atoms as ring members.

The term “hemoglobin” as used herein refers to any hemoglobîn protein, including normal hemoglobin (Hb) and sickle hemoglobin (HbS).

“Heteroaryl” refers to a cyclic or polycyclic radical having at least one aromatic ring and from one to five ring heteroatom selected from N, O, and S, and optionally one or more oxo (=0) substituents attached to one or more carbon ring atoms, and wherein the nitrogen and sulfur ring atoms are optionally oxidized. A heteroaryl group can be attached to the remainder of the molécule through a heteroatom or through a carbon atom and can contain 5 to 10 carbon atoms. Heteroaryl groups include polycyclic aromatic ring(s) fused to non-aromatic cycloalkyl or heterocycloalkyl groups, and where the point of attachaient to the remainder of the molécule can be through any suitable ring atom of any ring. In a polycyclic heteroaryl group, the ring heteroatom(s) can be in either an aromatic or non-aromatic ring or both. The term “aromatic ring” include any ring having at least one planar résonance structure where 2n+2 pï électrons are delocalized about the ring. Examples of heteroaryl groups include, but are not limited to, imidazopyridinyl groups, pyrrolopyridinyl groups, pyrazolopyridinyl groups, triazolopyridinyl groups, pyrazolopyraziny! groups, pyridinyl groups, pyrazinyl groups, oxazolyl groups, imidazolyl groups, triazolyl groups, tetrazolyl groups, pyrazolyl groups, quinolinyl groups, isoquinolinyl groups, indazolyl groups, benzooxazolyl groups, naphthyridinyl groups, and quinoxalinyl groups. Other non-limiting examples of heteroaryl groups include xanthine, hypoxanthine, 5-benzothiazolyl, purinyl, 2benzimïdazolyl, benzopyrazolyl, 5-indolyl, azaindole, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, 6-quinolyl 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1pyrazolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl and 4pyrimidyl. “Bicyclic heteroaryl” refers to a heteroaryl radical that contains two rings.

The term “heterocycloalkyl” refers to a cycloalkyl group containing at least one ring heteroatom and optionally one or more oxo substituents. As used herein, the term “heteroatom” is meant to include oxygen (O), nitrogen (N), and sulfur (S), wherein the heteroatoms are optionally oxidized, and the nitrogen atom(s) are optionally quatemized. Each heterocycle can be attached at any available ring carbon or heteroatom. Each heterocycle may hâve one or more rings. When multiple rings are présent, they can be fused together. Each heterocycle typically contains 1,2,3,4 or 5, independently selected heteroatoms. Preferably, these groups contain 1, 2,3,4,5,6,7,8,9 or 10 carbon atoms, 0,1,

2,3,4 or 5 nitrogen atoms, 0,1 or 2 sulfur atoms and 0,1 or 2 oxygen atoms. More preferably, these groups contain 1,2 or 3 nitrogen atoms, 0-1 sulfiir atoms and 0-1 oxygen atoms. Non-Iimiting examples of heterocycle groups include morpholin-3-one, piperazine-2one, piperazin-1-oxide, piperidine, morpholine, piperazine, isoxazoline, pyrazoline, imidazoline, pyrrolidine, and the like.

“Halo” or “halogen” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl”, are meant to include alkyl in which one or more hydrogen is substituted with halogen atoms which can be the same or different, in a number ranging from one up to the maximum number of halogens permitted e.g. for alkyl, (2m'+I), where m* is the total number of carbon atoms in the alkyl group. For example, the terni “haloCl-8alkyl” is meant to include difluoromethyi, trifluoromethyl, 2,2,2- tri fluoroethyl, 4-chlorobutyI, 3-bromopropyl, and the like. The term “haloalkenyl, and “haloalkynyl” refers to alkenyl and alkynyl radicals having one or more halogen atoms. Additionally, term “haloalkoxy” refers to an alkoxy radical substituted with one or more halogen atoms. In one group of embodiments, the haloakyl, haloalkenyl, haloalkynyl, and haloalkoxy groups hâve from one to 5 or from one to 3 halo atoms. Examples of haloalkoxy groups include difluoromethoxy and trifluoromethoxy. In one group ofembodiments, the halo atoms ofthe haloalkenyl and haloalkynyl groups are attached to the alîphatic portions of these groups.

The terms “optional” or “optionaily” as used throughout the spécification means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “heteroaryl group optionaily substituted with an alkyl group means that the alkyl may but need not be présent, and the description includes situations where the heteroaryl group is substituted with an alkyl group and situations where the heteroaryl group 25 is not substituted with the alkyl group.

“Oxo” refers to the divalent atom =0.

In each of the above embodiments designating a number of atoms e.g. “Ci-g is meant to include ail possible embodiments that hâve one fewer atom. Non-Iimiting examples include C14, C1.5, C|-e, Ci.7, C2-8» C2.7, C3.8, C3.7 and the like.

The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the présent invention contain relatively acidic functionalities, base addition salts can be obtained 6 by contacting the neutral form of such compounds with a sufïicient amount of the desired base, either neat or in a suitable inert solvent. Examples of salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferrie, ferrous, lithium, magnésium, manganic, manganous, potassium, sodium, zinc and the like. Salts derived from pharmaceutically-acceptable organic bases include salts ofprimary, secondary and tertiary amines, including substituted amines, cyclic amines, naturallyoccurring amines and the like, such as arginine, betaine, cafïeine, choline, N,N’dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethyl enedi ami ne, N-ethyl morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. When compounds of the présent invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a suffirent amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencaibonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensul furie, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic,p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge, S.M. et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 66:1 -19, 1977). Certain spécifie compounds of the présent invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

The neutral forms of the compounds maybe regenerated by contacting the sait with a base or acid and isolating the parent compound in the conventîonal manner. The parent form of the compound differs from the various sait forms in certain physical properties, such as solubîlity in polar solvents, but otherwise the salts are équivalent to the parent form of the compound for the purposes of the présent invention.

The term “pharmaceutically acceptable carrier or excipient” means a carrier or excipient that is useful in preparing a pharmaceutical composition that is generally safe, nontoxic and neither biologically nor otherwise undesirable, and includes a carrier or excipient that is acceptable for veterinary use as well as human pharmaceutical use. A “pharmaceutically acceptable carrier or excipient” as used in the spécification and daims includes both one and more lhan one such carrier or excipient.

The terms “pharmaceutically effective amount, “therapeutically effective amount” or “therapeutically effective dose” refers to the amount of the subject compound that will elicit the bîologïcal or medical response of a tissue, System, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. The term “therapeutically effective amount” includes that amount of a compound that, when administered, is sufïïcient to prevent development of, or alleviate to some extent, one or more of the symptoms of the condition or disorder being treated. The therapeutically effective amount will vary depending on the compound, the disorder or condition and its severity and the âge, weight, etc., of the mammal to be treated.

“Protecting group” refers to a group of atoms that, when attached to a reactive functional group in a molécule, mask, reduce or prevent the reactivity of the functional group.

Typically, a protecting group may be selectively removed as desired during the course of a synthesïs. Examples of protecting groups can be found in Greene and Wuts, Protective Groups in Organic Chemistiy, 3^ri Ed., 1999, John Wiley & Sons, NY and Harrison étal., Compendium of Synthetic Organic Methods, Vols. 1-8,1971-1996, John Wiley & Sons, NY. Représentative amino protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (“CBZ”), tert-butoxycaibonyl (“Boc”), trimethylsilyl (“TMS”), 2-trimethylsily!-ethanesulfonyl (“TES”), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (“FMOC”), nitroveratryloxycarbonyl (“NVOC”) and the like. Représentative hydroxy protecting groups include, but are not limited to, those where the hydroxy group is either acylated or alkylated such as benzyl and trityl ethers, as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers (e.g., TMS or T1PPS groups) and allyl ethers.

The term “aldéhyde protecting group” refers to any known protecting group used to mask the aldéhyde functionality. Aldéhyde protecting groups include acetals and hemiacetals. The acetals and hemiacetals can be prepared from C].g alcohols or C2-8 diols. In 30 one group of embodiments, the aldéhyde protecting group is a five or six membered cyclic acetal formed from condensation ofthe aldéhyde with ethylene or propylene glycol. In another group of embodiments the aldéhyde protecting group is an imine or hydroxyimine. The aldéhyde protecting groups ofthe présent disclosure also include prodrug groups that convert the aldéhyde to a prodrug, where the aldéhyde is formed in vivo as the active agent under physiological conditions upon administration of the prodrug. The prodrug group can also serve to increase the bioavailability of the aldéhyde. In one group of embodiments, the prodrug group is hydrolyzed in vivo to the aldéhyde. In one group of embodiments, the aldéhyde protecting group is a thiazolidine or N-acetylthiazolidine prodrug group. In one group of embodiments, the aldéhyde protecting group is a thiazolidine prodrug group disclosed in US 6,355,661. In one group of embodiments the modulators provided herein are condensed with L-cysteine or a L-cysteine dérivative to form the corresponding thiazolidine protected aldéhyde prodrug. In one group of embodiments, the thiazolidine has the formula

O.

^N'R¹²H wherein R¹¹ is selected from the group consisting of OH, alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, N(R^l3)2 where R¹³ is independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryi, and substituted heteroaryi; R¹² is H or — L-R¹⁴, where L is cafbonyl or sulfonyl; R¹⁴ is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryi, and substituted heteroaryi; the wavy line signifies the point of attachment to the phenyl ring of the allosteric modulators disclosed herein; and the term “substituted” refers to substitution by one or more substituents selected from the group consisting of COOH, CHO, oxyacyl, acyloxy, cycloacyloxy, phénol, phenoxy, pyridinyl, pyrrolidinyl, amino, amido, hydroxy, alkoxy, cycloalkoxy, F, CI, Br,

NO2, cyano, sulfuryl, and the like. In one group of embodiments, provided are modulators having a thiazolidine protecting group where R¹¹ is alkoxy and R¹² is H, or where Rⁿ is OH and R¹² is -C(O)alkyl, or where R¹¹ isNH(heteroary!) and R¹² is -C(O)aIkyl.

The term “sickle celï disease” refers to diseases mediated by sickle hemoglobin (HbS) that results from a single point mutation in the hemoglobin (Hb). Sickle cell diseases 25 includes sickle cell anémia, sickle-hemoglobin C disease (HbSC), sickle beta-plusthalassaemia (HbS/β¹) and sickle beta-zero-thalassaemia (HbS/β⁰).

The “subject” is defined herein to include animais such as mammals, including, but not limîted to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mîce and the like. In preferred embodiments, the subject is a human.

“Tautomer” refers to altemate forms of a molécule that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryi 9 groups containing a -N=C(H)-NH- ring atom arrangement, such as pyrazoles, imidazoles, benzimîdazoles, triazoles, and tetrazoles. A person of ordinary skill in the art would recognize that other tautomeric ring atom arrangements are possible.

The terms “treat”, “treating”, “treatment and grammatical variations thereof as used herein, includes partially or completely delaying, alleviating, mitigating or reducing the intensity, progression, or worsening of one or more attendant symptoms of a disorder or condition and/or alleviating, mitigating or impeding one or more causes of a disorder or condition. Treatments according to the invention may be applied preventively, prophylactically, pallatively or remedially.

The symbol > when used in connection with a substituent signifies that the substituent is a divalent substituent attached to two different atoms through a single atom on the substituent.

The term “wavy line” signifies the point of attachment of the substituent to the remainder of the molécule. When the wavy line is not depicted as being specifically appended to a spécifie ring atom, the point of attachment can be to any suitable atom of the substituent. For example, the wavy line in the following structure:

is intended to include, as the point of attachment, any of the six substitutable carbon atoms.

Compounds that hâve the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement oftheir atoms in space are termed “stereoisomers”. “Stereoisomer” and “stereoisomers” refer to compounds that exist in different stereoisomeric forms if they possess one or more asymmetric centers or a double bond with asymmetric substitution and, therefore, can be produced as indivîdual stereoisomers or as mixtures. Stereoisomers include enantiomers and diastereomers. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molécule rotâtes the plane of polarized light and designated as dextrorotatory or levorotatory (i.c., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a racemic mixture. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures. The methods for the détermination of stereochemistry and the séparation of stereoisomers are well-known in the art (see discussion in Chapter 4 of Advanced Organic CHEMISTRY, 4th édition J. March, John Wiley and Sons, New York, 1992) differ in the chirality of one or more stereocenters.

The compounds of the présent invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with isotopes, such as for example deuterium (²H), tritium (³H), iodine-125 (^,JÎI) or carbon-14 (^Î4C). Ail isotopic variations of the compounds of the présent invention, whether radioactive or not, are intended to be encompassed within the scope of the présent invention.

Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming the terminal portion of the functîonality followed by the adjacent functîonality toward the point of attachment. For example, the substituent “alkoxyalkyl” refers to an akyl group that is substituted with alkoxy and “hydoxyalkyl” refers to an akyl group that is substituted with hydroxy. For both ofthese substituents, the point of attachment is at the alkyl group.

It is understood that the définitions and formulas provided herein are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups). Such impermissible substitution patterns are well known to the skilled artisan.

II. Hemoglobin modulators

In one group of embodiments, provided is a compound of Formula (I):

Q ^Y'X R® R⁷

or a tautomer or pharmaceutically acceptable sait thereof, wherein Q is selected from the group consisting of aryl, heteroaryl, and heterocycloalkyl, each optionally substituted with one to three R^a;

Y is O or CR^laR^tb, where R^,a is H or halo and R^lb is selected from the group consisting of H, halo, and OH;

X is selected from the group consisting of O, >CH(CH₂)_nR⁸, and C(R⁹)₂ where n is 0 or I, R⁸ is OH, and R⁹ is independently H or halo; or Y-X taken together is -NHC(O)- or 5 C(O)NH·;

R², R³, R⁴, and R⁵ are independently selected from the group consisting of hydrogen, halo, R^b, OR^d, O(CH2)zOR^d, O(CH2)_zNR^dR^d, OC(O)R^e, SR^d, CN, NO2, CO2R^d, CONR^dR^d, C(O)R^d, OC(O)NR^dR^d, NR^dR^d, NR^dC(O)R* NR^dC(O)2R^e, NR^dC(O)NR^dR^d, S(O)R^e, S(O)2R^e, NR^dS(O)2R^e, S(O)2NR^dR^d, and Nj, where z is 0,1,2,3,4,5, or 6; or R³ is -(CH2)_pR^îa where p 10 is 0 or I and R^îa is OH;

R⁶ and R⁷ together form oxo or an aldéhyde protecting group, or R⁶ together with R^lb, R⁸, or R^s forms a cyclic ether where one of R^lb, R⁸, or R^îa is O, R⁶ is a bond, and R⁷ is selected from the group consisting ofOH, C|.j alkoxy, and haloCi-galkoxy, each R* is independently selected from the group consisting of halo, R^b, OR^d,

O(CH₂)_uOR^d, O(CH2)uNR^dR^d, O(CH2)_uNR^dC(O)R^e, O(CH2)uNR^dC(O)2R^e, O(CH2)uNR^dS(O)2R^e, NH2j -(CH2)kOC(O)R^e, -(CH2)_kSR^d, CN, NO2, -(CH^COXCu galkylJOH, -(CH2)kC02(Ct.galkyl)(heteroaryl)C(0)(CMalkyl), -(CH2)kCO2R^d, -(CH2)_kCONR^dR^d, -(CH2)kNR^dC(O)R^e, -(CH2)_kNR^dC(O)2R^e, -(CH2)_kC(O)R^d, ’ -(CH₂)_kOC(O)NR^dR^d, -NR^d(CH2)uOR^d, -NR^d(CH2)_uNR^dR^d, -NR^d(CH₂)_uNR^dC(O)R^e,

-NR^d(CH2)uNR^dC(O)2R^e, -NR^d(CH2)uNR^dS(O)2R^e, -(CH2)kNR^dC(O)R^e, -(CH2)_kNR^dC(O)2R^d, -(CH2)_kNR^dC(O)NR^dR^d, -(CH2)kS(O)R^c, -(CH2)_kS(O)₂R^c, -(CH2)kNR^dS(O)2R^e, -(CH2)kS(O)2NR^dR^d, Nj, -(CH2)_karyl optionally substituted with one to three R^c, -NR^d(CH2)karyl optionally substituted with one to three R^c, -(CH2)_kheteroaryl optionally substituted with one to three R^c, -NR^d(CH₂)_kheteroaryl optionally substituted with one to three R^c, -(CH2)kheterocycloalkyl optionally substituted with one to three R^c, and -NR^d(CH2)kheterocycloalkyl optionally substituted with one to three R^c where k is 0,1,2,3, 4,5, or 6 and u is 1,2,3,4,5, or 6;

each R^b is independently selected from the group consisting of Ci^alkyl, C₂.galkenyl, and C₂.g alkynyl, each optionally independently substituted with one to three halo, OR^d, or 30 NR^dR^d;

each R^c is independently selected from the group consisting of halo, C|.galkyl, haloCigalkyl, C₂.galkenyl, haloC₂.g alkenyl, C₂.galkynyl, haloC₂.galkynyl, (CH₂)_mOR^f, OC(O)R^!, SR^f,

CN, NO₂, CO₂R^f, CONR^rR^r, C(O)R^f, OC(O)NR^fR^f, (CH2)mNR^fR^f, NR^rC(O)R’, NR^rC(O)2R’, NR^fC(O)NR^fR^f, S(O)R^g, S(O)2R⁽, NR^fS(O)2R’, S(O)₂NR^rR^f, N₃, heteroaryl optionally substituted with one to three R^h, and heterocycloalkyl optionally substituted with one to three R^h where m is selected from the group consisting of 0,1,2,3,4,5, and 6;

each R*¹ is independently selected from the group consisting of halo, Ci.galkyl, haloCi. galkyl, OR¹, OC(O)R, SR¹, NO2, CO2R^J, CONR^jR^j, C(O)R^j, OC(O)NR^jR^j, NR^JR^j, NR^jC(O)R', NR^jC(O)2R‘, NR^JC(O)NR^jR^j, S(O)R', S(O)2R*. NR^jS(O)2R', and S(O)₂NR^jR^j;

R^d, R^r, and R¹ are each is independently selected from the group consisting of hydrogen, Cj.g alkyl, haloCi-galkyl, C₂.g alkenyl, hatoC₂^alkenyl, C₂.g alkynyl, and hatoC₂. gatkynyl; and

R^e, R⁸, and R* are each is independently selected from the group consisting of Cj. galkyl, haloCj.galkyl, C₂.g alkenyl, haloC₂.₈a1kenyl, C₂.g alkynyl, and haloC₂.galkynyl.

In one group of embodiments, X and Y are not both O.

In one group of embodiments, when X is O, R^lb is not OH.

In one group of embodiments, when Y is O, and n is 0, R⁸ is not OH.

In one group of embodiments, when R⁶ and R⁷ together are oxo, Y is CH₂, X is O or CH₂, and R^s is H, halo, OH, CHO, or OCHj, then Q is V or W.

In one group of embodiments, V is selected from the group consisting of

containing three to four ring nitrogen atoms; wherein V is optionally substituted with one to 5 three R; and

W is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, and pyridine-4-

N'N ,N'N N-N , ⁿ4 m Q m x ^ν·λ yl, , ”, and , wherein W is optionally substituted with one to three R* or is substituted with one to three R¹ when W is pyridin-2-yl, pyridin-3-yl, or pyridine-4-yl, and wherein the wavy line signifies the point of attachment to Y, provided that when V is

optionally substituted with one R\ then at least one of R², R³, R⁴, and R^s is OR^d; and provided that when V is

, n N , then V is substituted with one to three R^a.

In one group of embodiments, z is 0. In another group ofembodiments, z is 1. In yet another group of embodiments, z is 2. In still another group ofembodiments, z is 3. In another group ofembodiments, z is 4. In yet another group ofembodiments, z is 5. In still another group of embodiments, z is 6.

In one group of embodiments, provided is a compound of Formula (la):

Q

or a tautomer or pharmaceuticaily acceptable sait thereof, wherein Q is selected from the group consisting of aryl, heteroaryl, and heterocycloalkyl, each optionally substituted with one to three R’;

Y is O or CR^leR^lb, where R¹¹ is H or halo and R^Ib is selected from the group consisting of H, halo, and OH;

X is selected from the group consisting of O, >CH(CH₂)_nR⁸, and C(R⁹)₂ where n is 0 or 1, R* is OH, and R⁹ is independently H or halo;

R², R³, R⁴, and R³ are independently selected from the group consisting of hydrogen, halo, R^b, OR^d, OC(O)R^e, SR^d, CN, NO₂, CO₂R^d, CONR^dR^d, C(O)R^d, OC(O)NR^dR^d, NR^dR^d,

NR^dC(O)R\ NR^dC(O)₂R^e, NR^dC(O)NR^dR^d, S(O)R^e, S(O)2R^e, NR^dS(O)2R\ S(O)₂NR^dR^d, and N3; or R³ is -(CH₂)_pR^3a where p is 0 or 1 and R^îa is OH;

R⁶ and R⁷ together form oxo or an aldéhyde protecting group, or R⁶ together with R^lb, R*, or R³ forms a cyclic ether where one of R^lb, R⁸, or R^3a is -O-, R⁶ is a bond, and R⁷ is 15 selected from the group consisting of OH, Ci-galkoxy, and haloCi-galkoxy, each R* is independently selected from the group consisting of halo, R^b, OR^d,

OC(O)R^e, SR^d, CN, NO2, CO2R^d, CONR^dR^d, C(O)R^d, OC(O)NR^dR^d, NR^dC(O)R^e, NR^dC(O)2R^d, NR^dC(O)NR^dR^d, S(O)R^e, S(O)2R^e, NR^dS(O)2R^e, S(O)₂NR^dR^d, Nj, aryl optionally substituted with one to three R^c, heteroaryl optionally substituted with one to three 20 R^c, and heterocycloalkyl optionally substituted with one to three R^c;

each R^b is independently selected from the group consisting of Ci^alkyl, C₂.galkenyl, and C₂.g alkynyl, each optionally independently substituted with one to three halo, OR^d, or NR^dR^d;

each R^c is independently selected from the group consisting of halo, Cj-galkyl, halo

Ci-ealkyl, C₂.galkenyl, haloC₂.g alkenyl, C₂._galkynyl, haloC₂.galkynyl, (CH₂)_mOR^f, OC(O)R⁸,

SR^r, CN, NO2, CO2R^f, CONR^fR^r, C(O)R^r, OC(O)NR^fR^r, (CH2)_mNR^fR^f, NR^fC(O)R⁸,

NR^fC(O)2R>, NR^rC(O)NR^rR^f, S(O)R', S(O)2R', NR^fS(O)₂R· S(O)₂NR^fR^f, and Nj where m is selected from the group consisting of 0,1,2,3,4,5, and 6;

J f each R and R is independentiy selected from the group consisting ofhydrogen, C|.j alkyl, haloCi.galkyl, C₂.e alkenyl, haloC₂.gaIkenyl, C₂-8alkynyl, and haloC₂.8alkynyl; and each R^e and R* is independentiy selected from the group consisting of Ci^alkyl, haloC [.g alkyl, C₂.e alkenyl, haloC₂.8alkenyl, C2-8 alkynyl, and haloC₂^alkynyl;

provided that X and Y are not both O;

provided that when X is O, R^,b is not OH;

provided that when Y is O, and n is 0, R⁸ is not OH; and provided that when R⁶ and R⁷ together are oxo, Y is CH₂, X is O or CH2, and R⁵ is H, halo, OH, CHO, or OCHj, then Q is V or W;

V is selected from the group consisting of

and naphthalene contaînîng three to four ring nitrogen atoms; wherein V is optionally substituted with one to three R^a; and

W is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, and pyridine-4yi,

wherein W is optionally substituted with one to three R¹ or is substituted with one to three R¹ when W is pyridin-2-yl, pyridm-3-yl, or pyridine-4-yl, and wherein the wavy line signifies the point of attachment to Y, provided that when V is

optionally substituted with one R*, then at least one of R², R³, R⁴, and R³ is OR^d.

In one group of embodiments when R⁶ and R⁷ together are oxo, Y is CH2, X is O or CH2, and R⁵ is H, halo, OH, CHO, or OCH3, Q is not

In one group of embodiments, R⁶ and R⁷ together form oxo.

In one group of embodiments, R⁶ and R⁷ together form a thiazolidine.

In one group of embodiments, z is 0. In another group ofembodiments, z is 1. In yet another group ofembodiments, z is 2. In still another group ofembodiments, z is 3. In 10 another group of embodiments, z is 4. In yet another group of embodiments, z is 5. In still another group of embodiments, z is 6.

In one group of embodiments, provided is a compound having Formula (le), (Id), or de):

or a tautomer or pharmaceutically acceptable sait thereof, wherein R¹⁰ is selected from the group consisting of H, Cj.galkyl, and haloCi-galkyl.

In one group of embodiments, Q is a heteroaryl or heterocycloalkyl group optionally substituted with one to three R*.

In one group of embodiments, Q is a bicyclic heteroaryl or heterocycloalkyl group optionally substituted with one to three R*.

In one group of embodiments, Q is a bicyclic heteroaryl group optionally substituted with one to three R’.In one group of embodiments, Q is isoquinolin-4-yl optionally substituted with one to three R‘ wherein at least one R* is heteroaryl optionally substituted with one to three R^c. In one group ofembodiments at least one R* is heteroaryl attached to said Q at the ring atom adjacent to ring atom bearing Y. In one group of embodiments at least one R* is heteroaryl substituted with at least one Ci-galkyl. In one group ofembodiments at least one R heteroaryl is substituted with at least one methyl. In one group ofembodiments at least one R^a is pyrazolyl substituted with at least one Ci-galkyl. In one group of embodiments at least one R* is pyrazoyl substituted with at least one methyl. In one group of embodiments, R’ is pyrazol-5-yl. In one group of embodiments, R is 4-methylpyrazoI-5-yI.

In one group of embodiments, Q is a bicyclic heteroaryl group substituted with one to three R*.

In one group of embodiments, Q is V.

In one group of embodiments, V is selected from the group consisting of

In one group of embodiments, Q is substituted with CONR^dR^d, NR^dR^d, or heteroaryl optionally substituted with one to three R^c. In one group ofembodiments, Q is substituted with heteroaryl having one to two nitrogen ring atoms.

In one group of embodiments, Q is W.

In one group of embodiments, Q is selected from the group consisting of

N=N

In one group embodiments, at least one R^a is heteroaryl optionally substituted with one to three R^c.

In one group of embodiments at least one R* is heteroaryl attached to Q at the ring atom adjacent to ring atom bearing Y.

In one group of embodiments at least one R* is heteroaryl substituted with at least one Cj^alkyl, In one group ofembodiments at least one R* heteroaryl is substituted with at least one methyl.

In one group of embodiments at least one R* is pyrazolyl substituted with at least one Cj-galkyl. In one group ofembodiments at least one R“ is pyrazoyl substituted with at least one Cwalkyl. In one group ofembodiments, at least one R is pyrazol-5-yl. In one group of embodiments, at least one R“ is 4-methyl-pyrazoI-5-yI.

In one group of embodiments, Q is pyridin-2-yl, pyridin-3-yl, or pyridine-4-yl, said Q is optionally substituted with one to three R* wherein at least one R* is heteroaryl optionally substituted with one to three R^c. In one group ofembodiments at least one R^a is heteroaryl attached to said Q at the ring atom adjacent to ring atom bearing Y. In one group of embodiments at least one R’ is heteroaryl substituted with at least one Ci-galkyl. In one group of embodiments at least one R* heteroaryl is substituted with at least one methyl. In one group of embodiments at least one R¹ is pyrazolyl substituted with at least one Ci*galkyl. In one group of embodiments at least one R* is pyrazoyl substituted with at least one methyl. In one group of embodiments, R¹ is pyrazol-5-yl. In one group of embodiments, R* is 4methyl-pyrazol-5-yl.

In one group of embodiments, Q is substituted with at least one R* selected from the group consisting of-(CH₂)_kOH, -(CH₂)_kNH₂, -(CH₂)_kNH(C_Malkyl), -(CH₂)_kN(Ci₄alky1)(Ci. «alkyl), -(CH₂)_kNHC(O)(C].galkyl), -(CH₂)_kN(C_Malkyl)C(O)(C_Malkyl), -(CH₂)_kNHC(O)₂(Ci-galkyl), -(CH₂)_kN(C|.₈alkyl)C(O)₂(C_Malkyl),-(CH₂)_kNHS(O)₂(Cigalkyl), -(CH₂)_kN(Ci-galky1)S(O)₂(Ci-galkyl), and -(CH₂)_kheterocycloalkyl optionally substituted with one to three R^c. In some embodiments the heterocycloalkyl group is morpholino or piperazinyl optionally substituted with alkyl, -C(0)Ci4alkyl, -C(O)₂Ci-galkyl, or -S(O)₂Ci.galkyl.

In one group of embodiments, Q is substituted with at least one R* selected from the group consisting of-NR^d(CH2)uOH, -NR^d(CH2)_uNH₂, -NR^d(CH2)uNH(CMalkyl), -NR^d(CH2)_uN(C₁.₈alkyl)(Ci-galkyl),-NR^d(CH2)uNHC(O)(CMalkyl),-NR^d(CH2)_uN(Ci. galkyl)C(O)(Ci.galkyl),-NR^d(CH2)uNHC(O)2(Ci.8alkyl), -NR^d(CH2)_uN(C_Malkyl)C(O)₂(Ci. galkyl), -NR^d(CH2)uNHS(O)2(Ci.8alkyl), -NR^d(CH2)_üN(C].₈alkyl)S(O)₂(Ci.₈alkyl), and -NR^d(CH2)kheterocycloalkyl optionally substituted with one to three R^c where u is 1,2,3,4, 5, or 6 and k is 0,1, 2,3,4,5, or 6. In some embodiments, R^d is H or Ci.galkyl. In some embodiments the heterocycloalkyl group is morpholino or piperazinyl optionally substituted with alkyl, -C(O)Ci.galkyl, -C(O)2Ci .galkyl, or -S(O)₂C|.galkyl.

In one group of embodiments, Q is substituted with at least one R* selected from the group consisting of O(CH₂)_UOH, O(CH₂)_UNH₂,0(CH₂)_uNH(C|.galkyl), O(CH₂)_üN(Ci. galkyl)(Ci.galkyl), O(CH₂)_uNHC(O)(Ci.₈alkyl), O(CH₂)uN(C₁.₈alkyl)C(O)(C₁.₈a!kyl), O(CH₂)_uNHC(O)₂(Ci.₈alkyl), O(CH₂)_uN(C₁.₈alkyl)C(O)₂(C_I.₈alkyl), O(CH₂)_uNHS(O)₂(Cigalkyl), O(CH₂)_uN(C|.galkyl)S(O)₂(Ci.galkyl), and O(CH₂)_uheterocycloalkyl optionally substituted with one to three R^c where u is 1,2,3,4, 5, or 6. In some embodiments the heterocycloalkyl group is morpholino or piperazinyl optionally substituted with alkyl, -C(O)Ci.₈alkyl, -C(O)₂Cj.galkyl, or -S(O)₂C₁.₈alkyl.

In one group of embodiments, W is pyridîn-2-yl, pyridin-3-yl, or pyridine-4-yl, said W substituted with CN or CONR^dR^d.

In one group of embodiments, R² is H.

In one group of embodiments, R³ is H.

, In one group of embodiments, R^s is H.

In one group of embodiments, R⁴ is Cualkoxy.

In one group of embodiments, R², R³, R^s are H and R⁴ is Cualkoxy.

In one group of embodiments, R⁴ is methoxy.

In one group of embodiments, R⁴ is haloalkoxy. In one group of embodiments, R⁴is OCHFz. In one group ofembodiments, R⁴ is OCFj.

In one group of embodiments, R², R³, R⁴, and R^s are H.

In one group of embodiments, one of R², R³, R⁴, and R^s is selected from the group consisting of-O(CH₂)zOH, -O(CH2)_zO(Ci._galkyl), -O(CH₂)_ZNH₂, -O(CH₂)_zNH(Ci._galkyl), and -O(CH2)₂N(Ci._gaIkyl)(C]._galkyl) where z is 0,1,2,3,4,5, or 6.

In one group of embodiments, X is O.

In one group of embodiments, X is CH2.

In one group of embodiments, X is C(R⁹)₂ and at least one of R⁹ is F.

In one group of embodiments, Y is CH2.

In one group of embodiments, Y is CR’*R^Ib and at least one of R¹* orR^lbis F.

In one group of embodiments, z is 0. In another group of embodiments, z is 1. In yet another group ofembodiments, z is 2. In still another group ofembodiments, z is 3. In another group of embodiments, z is 4, In yet another group of embodiments, z is 5. In still another group of embodiments, z is 6.

In other embodiments, the invention provide a compound according to Formula (Ib):

Q

^Yx R® R⁷
^RŸi
	A
R⁴	(Ib)

or a tautomer or pharmaceutically acceptable sait thereof, wherein Q is selected from the group consisting of aryl, heteroaryl, and heterocycloalkyl, each optionally substîtuted with one to three R;

YisOorCH_2;

XisOorCH_2;

A «

R and R are independently selected from the group consisting of hydrogen, halo, R ,

OR^d, -O(CH2)zOR^d, -O(CH2)_zNR^dR^d, OC(O)R^e, SR^d, CN, NO2, CO2R^d, CONR^dR^d, C(O)R^d, OC(O)NR^dR^d, NR^dR^d, NR^dC(O)R^e, NR^dC(O)2R^e, NR^dC(O)NR^dR^d, S(O)R^e, S(O)2R^e, NR^dS(O)2R^e, S(O)2NR^dR^d, and Nj,where z is 0,1,2,3,4,5, or 6; or R^s is -(CH2)_pR^îa where p is 0 or 1 and R^îa is OH;

R⁴ is selected from the group consisting of hydrogen and OR^d;

R⁵ is selected from the group consisting of hydrogen, halo, and OR^d;

R⁶ and R⁷ together form oxo or an aldéhyde protecting group;

each R* is independently selected from the group consisting of halo, R^b, OR^d, O(CH₂)_uOR^d, O(CH2)uNR^dR^d, O(CH2)_uNR^dC(O)R^e, O(CH2)uNR^dC(O)2R^e,

O(CH₂)_uNR^dS(O)2R', NH2, -(CH2)kOC(O)R\ -(CH2)kSR^d, CN, NO2, -(CH₂)_kCO2(Ci.

_galkyl)OH, -(CH₂)_kC0₂(C₁._?alkyl)(heteroaryl)C(0)(C|._galkyl), -(CH₂)_kCO₂R^d, -(CH₂)_kCONR^dR^d, -(CH2)kNR^dC(O)R^e, -(CH2)_kNR^dC(O)2R^e, -(CH2)_kC(O)R^d, -(CH₂)_kOC(O)NR^dR^d, -NR^d(CH2)uOR^d, -NR^d(CH2)_uNR^dR^d, -NR^d(CH₂)_uNR^dC(O)R^e, -NR^d(CH2)uNR^dC(O)2R^e, -NR^d(CH2)uNR^dS(O)2R^e, -(CH2)kNR^dC(O)R^e, -(CH2)_kNR^dC(O)₂R^d,

-(CH₂)_kNR^dC(O)NR^dR^d, -(CH2)kS(O)R^e, -(CH2)_kS(O)₂R^e, -(CH2)kNR^dS(O)2R^e, -C(O)(CH₂)_kNR^dS(O)2R^e, -(CH2)_kC(O)NR^dS(O)₂R^e, -(CH2)kS(O)2NR^dR^d, Nj, -(CH2)_karyl optionally substîtuted with one to three R^e, -NR^d(CH2)karyl optionally substîtuted with one to three R^e, -(CH2)_kheteroaryl optionally substîtuted with one to three R^c, -NR^d(CH2)kheteroaryl optionally substîtuted with one to three R^c, -(CH2)_kheterocycloaIkyl optionally substîtuted with one to three R^c, and -NR^d(CH₂)_kheterocycIoaIkyl optionally substîtuted with one to three R^e where kis 0,1,2,3,4,5, or 6 and uis 1,2,3,4,5, or 6;

each R^b is independently selected from the group consisting of Cj^alkyl, C₂^alkenyl, and C₂.g alkynyl, each optionally independently substîtuted with one to three halo, OR^d, or NR^dR^d;

each R^c is independently selected from the group consisting of halo, C|.galkyl, haloCigalkyl, C₂.galkenyl, haloC₂.galkenyI, C₂.galkynyl, haIoC₂._gaIkynyl, (CH₂)_mOR^f, OC(O)R^g, SR^f,

CN, NO₂, (CH₂)_mCO₂R^f, CONR^fR^f, C(O)R^f, OC(O)NR^fR^f, (CH2)mNR^fR^f, NR^fC(O)R^g, NR^fC(O)2R⁸, NR^fC(O)NR^fR^f, S(O)R⁸, S(O)2R⁸, NR^fS(O)2R⁸, S(O)2NR^fR^f, Nj, (R^f)mSiC|. s alkyl, heteroaryl optionally substituted with one to three R^h, cycloalkyl optionally substituted with one to three R^h, and heterocycloalkyl optionally substituted with one to three R^h where m is selected from the group consisting of 0,1,2,3,4,5, and 6;

each R^h is independently selected from the group consisting ofhalo, Cj-galkyl, haloCt. galkyl, OR^J, OC(O)R, SR^J, NO2, CO2R^j, CONR^jR^j, C(O)R^J, OC(O)NR^jR^J, NR^jR^j, NR^JC(O)R’, NR^jC(O)2R’, NR^jC(O)NR^JR^j, S(O)R’, S(O)2R‘, NR^jS(O)2R*, and S(O)₂NR^jR^J;

R^d, R^f, and R^ are each independently selected from the group consisting of hydrogen, Cj.g alkyl, haloCt-galkyl, C₂.galkenyl, haloC₂.galkenyl, C₂.g alkynyl, and haloC₂.galkynyl; and

R^e, R®, and R* are each independently selected from the group consisting of Ct-galkyl, haloCi-galkyl, C₂.g alkenyl, haloC₂.galkenyl, C₂.g alkynyl, and haloC₂_galkynyl;

provided that X and Y are not both O;

provided that at least one of R⁴ and R⁵ is H;

provided that if R⁴ is OR^d, then Q is not phenyl, pyridinyl, or imidazo[l,2-a]pyridin-2yl, R* is not oxo, oxido, or halo, and X is O, provided that if R⁵ is OR^d, then R* is not oxo, oxido, or halo; and provided that if R²-R^s are H, then Q is not phenyl.

In one group of embodiments, the invention provides a compound of formula Ib, or a tautomer or pharmaceutically acceptable sait thereof, wherein R⁶ and R⁷ together form oxo.

In one group of embodiments, the invention provides a compound of formula Ib, or a tautomer or pharmaceutically acceptable sait thereof, wherein R⁵ is selected from the group consisting of hydrogen and OR^d.

In one group of embodiments, the invention provides a compound of formula Ib, or a tautomer or pharmaceutically acceptable sait thereof, wherein R^s is selected from the group consisting of hydroxy and fluoro.

In one group of embodiments, the invention provides a compound of formula Ib, wherein R² and R³ are independently selected from the group consisting of hydrogen, R^b,

0R^d, O(CH2),OR^d,O(CH2),NR^dR^d, OC(O)R', CChR¹¹, CONR^dR^d, and C(O)R^d, where z is 1, 2, or 3.

In one group of embodiments, the invention provides a compound of formula Ib, wherein R² and R³ are H.

In one group of embodiments, the invention provides a compound of formula Ib, wherein Q is seiected from the group consisting of :

and wherein Q is optionally substituted with one to three R¹.

In one group of embodiments, the invention provides a compound of formula Ib, wherein Q is seiected from the group consisting of an imidazopyridinyl group, a pyrrolopyridinyl group, a pyrazolopyridinyl group, a triazolopyridinyl group, a pyrazolopyrazinyl group, a pyridinyl group, a pyrazinyl group, an oxazolyl group, an imidazolyl group, a triazolyl group, a tetrazolyl group, a pyrazolyl group, a quînolinyl group, an isoquinolinyl group, and indazolyl group, a benzooxazolyl group, a naphthyridinyl group, a quinoxalinyl group; and wherein Q is optionally substituted with one to three R¹.

In one group of embodiments, the invention provides a compound of formula Ib, wherein z is 0. In another group of embodiments, z is 1. In yet another group of embodiments, z is 2. In still another group ofembodiments, z is 3. In another group of embodiments, z is 4. In yet another group ofembodiments, z is 5. In still another group of embodiments, z is 6.

In other embodiments, the invention provide a compound according to Formula le:

Q

R⁴ (le) or a tautomer or pharmaceutically acceptable sait thereof, wherein:

YisOorCH_2;

XisOorCH*

Q is selected from the group consisting of:

i) imidazopyridinyl, methylimidazopyridinyl, indazolyl, pyrrolopyridinyl, pyrrolopyrazinyl, pyrazolopyridinyl, pyrazolopyrazinyl, and quînolinyl, each of which is optionally substituted with one to three R^a; wherein

R², R³, R⁴, and R^s, are independently selected from the group consisting of hydrogen, halo, R^b, OR^d, O(CH2)zOR^d, O(CH2)_zNR^dR^d, OC(O)R^e, SR^d, CN, NO2, CO2R^d, CONR^dR^d, C(O)R^d, OC(O)NR^dR^d, NR^dR^d, NR^dC(O)R^e, NR^dC(O)2R^e, NR^dC(O)NR^dR^d, S(O)R^e, S(O)2R^e, NR^dS(O)2R^e, S(O)₂NR^dR^d, and Nj where z is 1,2, or 3; and ii) pyridinyl and piperidinyl, each of which is optionally substituted with one to three R^e; wherein

A * J

R , R , and R are independently selected from the group consisting of hydrogen, halo, R^b, OR^d, O(CH2)zOR^d, O(CH2)₂NR^dR^d, OC(O)R^e, SR^d, CN, NO2, CO2R^d, CONR^dR^d, C(O)R^d, OC(O)NR^dR^d, NR^dR^d, NR^dC(O)R^e, NR^dC(O)2R^e, NR^dC(O)NR^dR^d, S(O)R^e, S(O)2R^e, NR^dS(O)2R^e, S(O)₂NR^dR^d, and Nj where z is 1,2, or 3; and

R^s is selected from the group consisting of halo and OR^d;

R⁶ and R⁷ together form oxo or an aldéhyde protecting group;

each R* is independently selected from the group consisting of halo, oxo, R^b, OR^d, O(CH₂)_uOR^d, O(CH2)uNR^dR^d, O(CH2)_uNR^dC(O)R^e, O(CH2)uNR^dC(O)2R^e, O(CH2)uNR^dS(O)2R^e, NH₂, -(CH₂)_kOC(O)R^e, -(CH2)kSR^d, CN, NO2, -(CH₂)_kCO₂(C₍. galkyl)OH, •(CH₂)_kC0₂(C_l4alkyl)(heteroaryl)C(0)(C₁.galkyl),-(CH₂)_kC0₂R^d, -(CH₂)_kCONR^dR^d, -(CH2)kNR^dC(O)R^e, -(CH2)_kNR^dC(O)2R^e, -(CH2)_kC(O)R^d, -(CH₂)_kOC(O)NR^dR^d, -NR^d(CH2)uOR^d, -NR^d(CH2)_uNR^dR^d, -NR^d(CH₂)_uNR^dC(O)R^e, -NR^d(CH2)uNR^dC(O)2R^e, -NR^d(CH2)uNR^dS(O)2R^e, -(CH2)kNR^dC(O)R^e, -(CH2)_kNR^dC(O)2R^d, -(CH2)_kNR^dC(O)NR^dR^d, -(CH2)kS(O)R^e, -(CH2)_kS(O)₂R^e, -(CH2)kNR^dS(O)2R^e, -C(O)(CH₂)_kNR^dS(O)2R^e, -(CH2)_kC(O)NR^dS(O)₂R^e, -(CH2)kS(O)2NR^dR^d, Nj, -(CH2)_karyl optionally substituted with one to three R^c, -NR^d(CH2)karyl optionally substituted with one to three R^c, -(CH2)_kheteroaryl optionally substituted with one to three R^c, -NR^d(CH₂)_kheteroaryl optionally substituted with one to three R^e, -(CH2)kheterocycloalkyl optionally substituted with one to three R^e, and -NR^d(CH2)_kheterocyclo alkyl optionally substituted with one to three R^c where k is 0,1,2,3,4,5, or 6 and u is 1,2,3,4,5, or 6;

each R^b is independently selected from the group consisting ofCi-galkyl, C₂. galkenyl, and C₂.galkynyl, each optionally independently substituted with one to three halo, OR^d,orNR^dR^d;

each R^c is independently selected from the group consisting of halo, C|.galkyl, haloC|.galkyl, C2.galkenyl, haloC2.galkenyl, C2.galkynyl, haloC2.galkynyl, (CH2)mOR^f, OC(O)R’, SR^f, CN, NO2, (CH₂)_mCO₂R^f, CONR^rR^r, C(O)R^r, OC(O)NR^rR^r, (CH2)mNR^fR^f, NR^fC(O)R^g, NR^rC(O)2R^g, NR^fC(O)NR^fR^f, S(O)R^l, S(O)2R*, NR^fS(O)2Rⁱ, S(O)2NR^fR^f, Nj, (R^f)mSiC].8aIkyl, heteroaryl optionally substituted with one to three R^h, cycloalkyl optionally substituted with one to three R , and heterocycloalkyl optionally substituted with one to three R^b where m is selected from the group consisting of 0, 1,2,3,4, 5, and 6;

each R^h is independentiy selected from the group consisting of halo, Cualkyl, haloC i-8 alkyl, OR^j, OC(O)R, SR^j, NO2, CO^, CONR^JR^j, C(O)R^j, OC(O)NR^JR^j, NR^jR^j, NR^JC(O)R‘, NR^JC(O)2R*, NR^jC(O)NR^jR^j, S(O)R‘, S(O)2R’, NR^jS(O)2R‘, and S(O)₂NR^jR^j;

R^d, R^f, and R* are each independentiy selected from the group consisting of hydrogen, Cm alkyl, haloCMûlkyl, Cm alkenyl, haloC₂4alkenyl, C₂^alkynyl, and haloC₂. salkynyl; and

R^e, R*, and R* are each independentiy selected from the group consisting of Ci. salkyl, haloCMalkyl, Cm alkenyl, haloC₂^alkenyl, C₂^alkynyl, and haloC₂. salkynyl.

In one group of embodiments, the invention provides a compound of formula le, wherein Q is selected from the group consisting of imidazo[l,5-a]pyridin-8-y], imidazo[l,5a]pyridin-6-yl, imidazo[l,5-a]pyridin-5-yl, imidazo[l,2-a]pyridin-8-yI, imidazo[l,2a]pyridin-7-yl, imidazo[l,2-a]pyridin-6-yl, imidazo[l,2-a]pyridin-5-yI, imida2o[l,2a]pyridin-3-yl, 8-methylimidazo[l,2-a]pyridin-2-yl, indazol-4-yl, pyrrolo[2,3-b]pyridin-4-yl, pyrrolof l,2-a]pyrazin-6-yl, pyrrolo[l ,2-a]pyrazin-4-yl, pyrazolo[3,4-b]pyridin-4-yl, pyra2olo[l,5-a]pyrazin-3-yl, and quinoIin-5-yl, each of which is optionally substituted with one to three R*.

In one group of embodiments, the invention provides a compound of formula le, wherein 2 is 1. In another group of embodiments, 2 is 2. In still another group of embodiments, 2 is 3.

In one group of embodiments, the invention provides a compound wherein: Y is CH_2; andXisCH₂.

In one group of embodiments, the invention provides a compound of formula le, wherein R² is selected from the group consisting of H and OR^d;

R³ is selected from the group consisting of H, CN, halo, and OR^d;

R⁴ is selected from the group consisting of H, CN, and OR^d: and

R^s is H.

In one group of embodiments, the invention provides a compound of formula le, wherein R⁴ is methoxy.

In one group of embodiments, the invention provides a compound of formula le, wherein Q is selected from the group consisting of pyridine-3-yl and piperidin-l-yl.

In one group of embodiments, the invention provides a compound of formula le, wherein R⁵ is selected from the group consisting of hydroxy and fluoro.

In one group of embodiments, the invention provides a compound of formula le, wherein R⁶ and R⁷ together form oxo.

In one group of embodiments, a compound is selected from Table 1 below or a tautomer or pharmaceutically acceptable sait thereof.

Table 1

Compound	Structure	Name
1	co Ό 0 ¢0	2-(imidazo[ 1,2-a]pyridin-8ylmethoxy)-5-methoxybenzaldehyde
2	CO Ό 0	4-formyl-3 -(imidazo[ 1,2-a]pyridin-8ylmethoxyjbenzonitrile
3	CO Ό 0 OA	2-(imidazo[ J ,2-a]pyridin-8ylmethoxy)-4-methoxybenzaldehyde

4	Γ1 ο ο φτ* Οχ	2-(imidazo[ 1,2-a]pyridin-6ylmethoxy)-5-methoxybenzaldehyde
5	Q Y lÿ” Οχ	2-(imidazo[l ,2-a]pyridin-2ylmethoxy)-5-methoxybenzaldehyde
6	•αο Ό 0	2-(imidazo[ 1,5-a]pyridïn-8ylmethoxy)-4-methoxybenzaldehyde
7	•00 Ό Ο ξΛ Οχ	2-(imi dazo[ 1,5-a]pyridin-8ylmethoxy)-5-methoxybenzaldehyde
8	Ck V 0 0 φΛ„ Οχ	2-(imidazo[l,2-a]pyridin-7ylmethoxy) -5 -methoxybenzal dehyde

9	Cb Ό 0 Os	2-(imidazo[ 1,2-a]pyridin-3ylmethoxy)-5-methoxybenzaldehyde
10	Ό 0 °x	5-methoxy-2-(quinolin-5ylmethoxy)benzaldehyde
11	X V^z	5-bromo-2-(imidazo[ 1,2-a]pyridin-8ylmethoxy)benzaldehyde
12	CO Ό 0 #	4-chloro-2-(imidazo[ 1,2-a]pyridin-8ylmethoxy)benzaldehyde
13	CO Ό 0	2-(imidazo[l,2-a]pyridin-8ylmethoxy)benzaldehyde

14	ço Ό Ο	4-fluoro-2-(imidazo[l,2-a]pyridin-8ylmethoxy)benzaldehyde
15	ço Ό Ο ^χ°'0^Λη	2-(imidazo[I,2-a]pyridin-8ylmethoxy)-3-methoxybenzaldehyde
16	¢0 φ^	2-(imidazo[l,2-a]pyridin-8ylmethoxy)-5-methylbenzaldehyde
17	co φ'*	5-methoxy-2-(pyrrolo[ 1,2-a]pyrazin-4ylmethoxy)benzaldehyde
18	Ν--, Ο 0	2-(imidazo[ 1,5-a]pyridin-6ylmethoxy)-4-methoxybenzaldehyde

19	ÇC^N Ό 0 Οχ	2-(imidazo[ 1,5-a]pyridîn-5ylmethoxy)-5-methoxybenzaldehyde
20	Ό 0 ¢/.- CN	3 -formyl-4-(imi dazo[ 1,5-a]pyri din-5 ylmethoxy)benzonitrile
21	<ο Ό 0 ¢/-	2-(( 1 H-pyrrolo[2,3-b]pyridin-4yl)methoxy)-5-methoxybenzaldehyde
22	¢0 q-	5-ethyl-2-(imidazo[ 1,2-a]pyridin-8yl methoxy)benzald ehyde
23	\ * ίΡ^ <1 <υ % 0 ¢/-	5-methoxy-2-(( 1 -m ethyl-1 H-indazol -4yl)methoxy)benzaldehyde

24	H Ό 0	5 -methoxy-2-((8-methylimi dazo[ 1,2a]pyridin-2-yl)methoxy)benzaldehyde
25	<y Ό 0 φ'¹	2-((1 H-indazol-4-yl)methoxy)-5methoxybenzaldehyde
26	ILa. dû Ρ% ÇH —0	2-((lH-pyrrolo[2,3-b]pyridin-4yl)methoxy)-5-methoxybenzal dehyd e
27	œ Ό O φΑ CN	3-fonuyl-4-(imidazo[l,2-a]pyridin-8ylmethoxy)benzonitrile
28	N^=\__ Vn3 Ό O φΑ	5-methoxy-2-(pyrrolo[ 1,2-a]pyrazin-6ylmethoxy)benzaldehyde

29	Ό 0	6-((2-formyl-4methoxyphenoxy)methyl)pyrrolo[ 1,2a]pyrazïne-7-cafbonitril e
30	^^Ny^CONH₂ Ό 0 φ^	6-((2-fonnyl-4methoxyphenoxy)methyl)pyrrolo[ 1,2a] pyrazine-7-carboxami de
31	<O ? « À ^0	2-(( 1 H-pyrazolo[3,4-b]pyridin-4yl)methoxy)-5-methoxybenza!dehyde
32	κΓ^ ^N_N M3 φΑ <k	5-methoxy-2-(pyrazolo[ 1,5-a]pyrazin- 3-ylmethoxy)benzaldehyde
33	(T 0 φΑ <k	5-methoxy-2-(pyrrolo[ 1,2-a]pyrazin-6ylmethoxy)benza!dehyde

34	/Γ^Ν ά <y ο φΑ	2-(imidazo[ 1,5-a]pyridin-6ylmethoxy)-5-methoxybenza1dehyde
35	ΌΓ Ο φΑ CN	3-formyl-4-(imidazo[l,2-a]pyridin-8yl methoxy)benzo nitril e
36	ΟΗ	3-(imidazo[l,2-a]pyridin-8-ylmethyl)- 1,3 -dihydroisobenzofuran-1 -ol
37	CÛ CT 0	2-(imidazo[ 1,2-a]pyridin-5ylmethoxy)-5-methoxybenzaldehyde
38	en Ο ΗΝ'Χ) Αφ	N-(2-formyl-4methoxyphenyl)imidazo[l,2a] pyri dîne-8-carboxamîd e

39	ÇO 0 HN^O X)	N-(2-formylphenyl)imi dazo [1,2a]pyridine-S-carboxamide
40	°γ^Νΐ	2-formyl-N-(imidazo[l,2-a]pyridin-8yl)benzamide
41	O Ό 0 (X Οχ	5-methoxy-2-(pyridin-3ylmethoxy)benzaldehyde
42	O^OH Ό 0 (X:	4-((2-formyI-3hydroxyphenoxy)methyl)benzoic acid
43	N^i ^Ν'^Ν\-^Ί3 0 ^ré0	2-hydroxy-6-((2-( 1 -isopropyl-lHpyrazol-5 -yl)pyrid in-3 yl)methoxy)benzaldehyde

44	n-n o^' Ό 0 ôt	2-((3 -(2 H -tetrazol-5-yl)benzyl )oxy) -6hydroxybenzaldehyde
45	N-NH >1 » N ,N Û Ό O	2-((4-(2H-tetrazoI-5-yl)benzyl)oxy)-6hydroxybenzaldehyde
46	1 o^o Ό 0 ex	methyl 4-((2- formylphenoxy)methyl)benzoate
47	Ck,OH Ό O (X	4-((2-formylphenoxy)methyl)benzoic acid
48	(/ Ό 0 (X	methyl 3-((2- formylphenoxy)methyl)benzoate

49	vO-o éç 0	2-bromo-3-((2-(l -isopropyl-lHpyrazol-5-yl)pyridin-3yl)methoxy)benzal dehy de
50	fA jpi vY ch OH	2- hydroxy-6-((2-( 1 -(2,2,2trifluoroethyl)-l H-pyrazol-5-yl)pyridin- 3- yl)methoxy)benzaldehyde
51	p NxJJ VJ dr° OH	2-hydroxy-6-((2-(l-(3,3,3> trifluoropropyl)-l H-pyrazol-5yl)pyridin-3-yl)methoxy)benzaldehyde
52	/v9 V\ ^0 0	2-fluoro-6-((2-(l-(2,2,2-trifluoroethyl)- 1 H-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde
53	£k k o	2-fluoro-6-((2-(l-(3,3,3trifluoropropyl)-1 H-pyrazol-5yl)pyri di n-3 -yl)methoxy)benzaldehyde

54	Ν^ί ⁿ'ⁿx-^o 0 ^rcX-	2-fluoro-6-((2-( 1 -isopropyl -1Hpyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde
55	O^.OH δ A-	l-(2-formyl-3- hydroxyphenethyl)piperidine-4carboxylic acid

In one group of embodiments, the compound is selected from:

2-(imidazo[l,2-a]pyridin-8-ylmethoxy)-5-methoxybenzaldehyde,

2-(imidazo[ 1,2-a]pyridin-2-ylmethoxy)-5-methoxybenzaldehyde,

2-(imidazo[ 1,5-a]pyridin-8-ylmethoxy)-5-methoxybenzaldchyde,

5-methoxy-2-(quinolin-5-ylmethoxy)benzaldehyde,

5-methoxy-2-((l-methyl-lH-indazol-4-yl)methoxy)benzaldehyde, 5-methoxy-2-((8-methylimidazo[l,2-a]pyridin-2-yl)methoxy)benzaldehyde,

2-((1 H-indazol-4-yl)mcthoxy)-5-methoxybenzaldehyde,

5-methoxy-2-(pyridin-3-ylmethoxy)bcnzaldehyde,

2-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)-5-methoxybenzaldehyde,

2-hydroxy-6-((2-(l -isopropyl-1 H-pyrazol-5-yl)pyridin-3-yl)methoxy)benza]dehyde,

2-((3-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehydc,

2-((4-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde, methyl 4-((2-formylphenoxy)methyl)benzoate,

4-((2- formylphenoxy) methyl )benzo ic acid, methyl 3-((2-formylphenoxy)methyl)benzoate,

2-bromo-3-((2-(I-isopropyI-IH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, 2-hydroxy-6-((2-(l-(2,2,2-trifluoroethyI)-lH-pyrazoI-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-hydroxy-6-((2-( I -(3,3,3-trifluoropropyl)-1 H-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-fluoro-6-((2-( 1 -(2,2,2-trifluoroethyl)-1 H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, 2-fluoro-6-((2-(I-(3,3,3-trifluoropropjl)-lH-pyrazol-5-yl)pyridin-3· yl)methoxy)benzaldehyde,

2-fluoro-6-((2-(I-isopropyl-IH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, and l-(2-formyl-3-hydroxyphenethyI)piperidine-4-carboxylic acid, or a tautomer or pharmaceutically acceptable sait thereof.

In one group of embodiments, provided is a compound in any of the Examples or

Tables. In another group of embodiments, provided are any combinations of subembodiments as disclosed herein including any combination of éléments disclosed herein including the a sélection of any single éléments.

In one group of embodiments, provided is a pharmaceutical composition comprising a compound of any of the above embodiments or a tautomer or pharmaceutically acceptable sait thereof.

In one group of embodiments, provided is a pharmaceutical composition comprising a compound that is

OMe or a pharmaceutically acceptable sait thereof.

The compounds of the présent invention may be prepared by known organic synthesis techniques, including the methods described in more detail in the Examples.

In one group of embodiments, provided is an intermediate compound used in the préparation of the compounds disclosed herein.

In one group of embodiments, provided are methods for preparing the compounds disclosed herein.

For example, Scheme I shows a synthetic route for the synthesis of the compounds of Formula (I) where X is O and Y is CH₂. Phénol 1.1 is contacted with intermediate 1.2 in the presence of base under ether forming conditions to gi ve ether 1J, where Lg represents a leaving group such as a halogen leaving group. Conversely, when X is O and Y is CH₂, the compounds of Formula (I) can be prepared using the appropriate starting materials where the

OH moiety of intermediate 1.1 is replaced with a leaving group and the Lg group of intermediate 1.2 is replaced with an OH group.

Scheme I

Q-CH₂-Lg

1.1

1.2

1.3

Scheme II shows an example of a synthetic route for the synthesis of the compounds 15 of Formula (I) where X and Y are CH₂. Alkene 2.1 is contacted with alkene 2.2 under metathesis forming conditions in the presence of an appropriate transition métal catalyst. Suitable catalysts include ruthénium catalysts such as Grubbs* catalyst. Product 23 is then hydrogenated to give compound 2.4.

Scheme II

2·¹

2.2

Scheme III shows an example of a synthetic route for the synthesis of the compounds ofFormula (I) where R⁶ together with R^lb form a cyclic ether. Compound 3.1, is reacted with diethylphosphite and a base such as sodium methoxide to give intermediate 3.2, that is then condensed with aldéhyde 33 to give alkene 3.4. Treatment of the alkene with H₂ under hydrogénation conditions gives lactone 3.4, which is then reduced with a suitable reducing agent such as LÎBHEtj to give cyclic hemiacetal 3.5.

Scheme III

Scheme IV shows an example of synthesis of the compounds of Formula (I) where 10 Q is pyridine-3-yl and R¹ heteroaryi. Acid 4.1 is reduced to alcohol 4.2 using known methods such as by forming the anhydride (e.g. treatment with triethylamine and i-butyl chloroformate) followed by réduction with NaBH₄. Alcohol 4.2 is converted to chloride 43 such as by treatment with thionyl chloride. Coupling of the halide with alcohol 4.4 under ether forming conditions gives the precursor 4.5 that can be functionalized with a variety to 15 heteroaryi R* groups. For example, 4.5 can be coupled with pyrazole 4.6 under known organometallic coupling conditions (e.g. Pd(PPh₂)4 ) to give 4.7, where PG is a nitrogen protecting group such as a sïlyl protecting group that can be removed to give the product 4.8.

Scheme IV

4.5

PG

4.6

4.8

4.7

One skilled in the art will recognize that in certain embodiments it may be advantageous to use a protecting group strategy. The protecting group can be removed using methods known to those skilled in the art.

In one group of embodiments, certain of the compounds disclosed herein may generally be utilized as the free base. Altematively, certain ofthe compounds may be used in the form of acid addition salts.

It is understood that in another group of embodiments, any of the above embodiments may also be combined with other embodiments listed herein, to form other embodiments ofthe invention. Similarly, it is understood that in other embodiments, listing of groups includes embodiments wherein one or more ofthe éléments of those groups is not included.

ΠΙ. Compositions and Methods of Administration

Depending on the intended mode of administration, the pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, preferably in 44 unit dosage form suitable for single administration of a précisé dosage. In addition to an effective amount of the active compound(s), the compositions may contain suitable pharmaceutically-acceptable excipients, including adjuvants which facilitate processing of the active compounds into préparations which can be used pharmaceutically. “Pharmaceutically acceptable excipient” refers to an excipient or mixture of excipients which does not interfère with the effectiveness of the biological activity of the active compound(s) and which is not toxic or otherwise undesirable to the subject to which it is administered.

For solid compositions, conventional excipients include, for example, pharmaceutical grades of mannitol, lactose, starch, magnésium stéarate, sodium saccharin, talc, cellulose, glucose, sucrose, magnésium carbonate, and the like. Liquid pharmacologicalty administrable compositions can, for example, be prepared by dissolving, dispersîng, etc., an active compound as described herein and optional pharmaceutical adjuvants in water or an aqueous excipient, such as, for example, water, saline, aqueous dextrose, and the like, to form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxillary excipients such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.

For oral administration, the composition will generally take the form of a tablet or capsule, or it may be an aqueous or nonaqueous solution, suspension or syrup. Tabtets and capsules are preferred oral administration forms. Tablets and capsules for oral use will generally include one or more commonty used excipients such as lactose and com starch. Lubricating agents, such as magnésium stéarate, are also typically added. When liquid suspensions are used, the active agent may be combined with emulsifying and suspending excipients. If desired, flavoring, coloring and/or sweetening agents may be added as well. Other optional excipients for incorporation into an oral formulation include preservatives, suspending agents, thickening agents, and the like.

Injectable formulations can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solubîlization or suspension in liquid prior to injection, or as émulsions or liposomal formulations. The stérile injectable formulation may also be a stérile injectable solution or a suspension in a nontoxic parenterally acceptable diluent or solvent. Among the acceptable vehictes and solvents that may be employed are water, Ringer's solution and isotonie sodium chloride solution. In addition, stérile, fixed oits, fatty esters or polyols are conventionally employed as solvents or suspending media.

The pharmaceutical compositions of this invention may also be formulated in lyophilized form for parentéral administration. Lyophilized formulations may be reconstituted by addition of water or other aqueous medium and then further diluted with a suitable diluent prior to use. The liquid formulation is generally a buffered, isotonie, aqueous solution. Examples of suitable diluents are isotonie saline solution, 5% dextrose in water, and buffered sodium or ammonium acetate solution. Pharmaceutically acceptable solid or liquid excipients may be added to enhance or stabilize the composition, or to facilitate préparation ofthe composition.

Typically, a pharmaceutical composition ofthe présent invention is packaged in a container with a label, or instructions, or both, indicating use of the pharmaceutical composition in the treatment of the indicated disease.

The pharmaceutical composition may additionally contain one or more other pharmacologically active agents in addition to a compound of this invention.

Dosage forms containing effective amounts ofthe modulators are within the bounds of routine expérimentation and within the scope of the invention. A therapeutically effective dose may vary dependîng upon the route of administration and dosage form. The représentative compound or compounds of the invention is a formulation that exhibits a high therapeutic index. The therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LD50 and EDjo- The LDjo is the dose léthal to 50% ofthe population and the EDjo is the dose therapeutically effective in 50% of the population. The LDjo and ED50 are determined by standard pharmaceutical procedures in animal cell cultures or experimental animais. It should be understood that a spécifie dosage and treatment regimen for any particular patient will dépend upon a variety of factors, including the activity of the spécifie compound employed, the âge, body weight, general health, sex and diet of the patient, and the time of administration, rate of excrétion, drug combination, judgment of the treating physicien and severity of the particular disease being treated. The amount ofactive ingredient(s) will also dépend upon the particular compound and other therapeutic agent, if présent, in the composition.

ZK Methods

In one group of embodiments, provided is a method for increasing tîssue oxygénation, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of the above embodiments or a tautomer or pharmaceutically acceptable sait thereof.

In one group of embodiments, provided is a method for treating a condition associated with oxygen deficiency, the method comprising administering to a subjcct in need thereof a therapeutically effective amount of a compound of any of the above embodiments or a tautomer or pharmaceutically acceptable sait thereof.

In one group of embodiments, provided is a method for treating sickle cell disease, cancer, a pulmonary disorder, stroke, high altitude sickness, an ulcer, a pressure sore, Alzheimer’s disease, acute respiratory disease syndrome, and a wound, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of the above embodiments or a tautomer or pharmaceutically acceptable 10 sait thereof.

In one group of embodiments, provided is a method for increasing tissue oxygénation or for treating a condition associated with oxygen deficiency, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound Formula (II):

Q

R⁴ (II) or a tautomer or pharmaceutically acceptable sait thereof, wherein Q is selected from the group consisting of aryl, heteroaryl, and heterocycloalkyl, each optionally substituted with one to three R“;

Y is O or CR^uR^lb, where R¹’ is H or halo and R^lb is selected from the group consisting of H, halo, and OH;

X is selected from the group consisting of O, >CH(CH2)_nR⁸» and C(R⁹)2 where n is 0 or I, R* is OH, and R⁹ is independently H or halo; or Y-X taken together is -NHC(O)- or C(O)NH-;

R², R³, R⁴, and R⁵ are independently selected from the group consisting of hydrogen, 25 halo, R^b, OR^d, -O(CH2)zOR^d, -O(CH2)_zNR^dR^d, OC(O)R^e, SR^d, CN, NO2, CO2R^d, CONR^dR^d, C(O)R^d, OC(O)NR^dR^d, NR^dR^d, NR^dC(O)R^e, NR^dC(O)2R^e, NR^dC(O)NR^dR^d, S(O)R^e, S(O)₂R^e,

NR^dS(O)2R^e, S(O)2NR^dR^d, and N3, where z is 0,1,2,3,4,5, or 6; or R⁵ is -(CH2)pR^5a where p is 0 or 1 and R^Sa is OH;

R⁶ and R⁷ together form oxo or an aldéhyde protecting group, or R⁶ together with R^lb, R*, or R^s forms a cyclic ether where one of R^lb, R⁸, or R^Sa is O, R⁶ is a bond, and R⁷ is selected from the group consisting of OH, Ci-galkoxy, and haloCj-galkoxy;

each R* is independently selected from the group consisting of halo, R^b, OR^d, O(CH₂)_uOR^d, O(CH2)uNR^dR^d, O(CH2)_uNR^dC(O)R^e, O(CH2)uNR^dC(O)2R^e, O(CH2)uNR^dS(O)2R^e, NH₂, -(CH₂)_kOC(O)R^e, -(CH2)kSR^d, CN, NO2, -(CH^CO^C,. galkyl)OH, -(CH₂)_kCO₂(Ci.₈alkyl)(heteroaryl)C(O)(Ci._galkyl), -(CH₂)_kCO₂R^d, -(CH₂)_kCONR^dR^d, -(CH2)kNR^dC(O)R^e, -(CH2)_kNR^dC(O)2R^e, -(CH2)_kC(O)R^d, (CH₂)_kOC(O)NR^dR^d, -NR^d(CH2)uOR^d, -NR^d(CH2)_uNR^dR^d, -NR^d(CH₂)_uNR^dC(O)R^e, -NR^d(CH2)uNR^dC(O)2R^e, -NR^d(CH2)uNR^dS(O)2R^e, -(CH2)kNR^dC(O)R^e, -(CH2)_kNR^dC(O)2R^d, -(CH2)_kNR^dC(O)NR^dR^d, -(CH2)kS(O)R^e, -(CH2)_kS(O)₂R^e, -(CH₂)_kNR^dS(O)2R^e, -(CH2)_kS(O)₂NR^dR^d, N₃, ‘(CH₂)_karyl optionally substituted with one to three R^c, -NR^d(CH2)karyl optionally substituted with one to three R^c, -(CH2)kheteroaryl optionally substituted with one to three R^c, -NR^d(CH₂)_kheteroaryl optionally substituted with one to three R^c, -(CH2)kheterocycloalkyl optionally substituted with one to three R^c, and -NR^d(CH2)_kheterocycloalkyl optionally substituted with one to three R^c where k is 0, 1,2, 3, 4, 5, or 6 and u is 1,2, 3,4,5, or 6;

each R^b is independently selected from the group consisting of Ci-galkyl, C₂^alkenyl, and C₂.g alkynyl, each optionally independently substituted with one to three halo, OR^d, or NR^dR^d;

each R^e is independently selected from the group consisting of halo, Ci-galkyl, haloC]. galkyl, C2.galkenyl, haloC2.g alkenyl, C2.galkynyl, haloC2.galkynyl, (CH2)mOR^r, OC(O)R⁸, SR^f, CN, NCh, CO2R^f, CONR^fR^f, C(O)R^f, OC(O)NR^fR^f, (CH2)mNR^rR^f, NR^rC(O)R^g, NR^fC(O)2R⁸, NR^fC(O)NR^fR^f, S(O)R⁸, S(O)2R⁸, NR^fS(O)2R^g, S(O)2NR^rR^f, N3, heteroaryl optionally substituted with one to three R^h, and heterocycloalkyl optionally substituted with one to three R^h where m is selected from the group consisting of 0,1,2, 3,4,5, and 6;

R^d, R^f, and R^ are each independently selected from the group consisting ofhydrogen, C|.g alkyl, haloCi-galkyl, C₂.g alkenyl, haloC₂.galkenyl, C₂.g alkynyl, and haIoC₂.galkynyl; and

R^e, R⁸, and R’ are each independently selected from the group consisting of C].galkyl, haloCi-galkyl, C₂.g alkenyl, haloC₂.galkenyl, C₂.g alkynyl, and haloC₂.galkynyI;

provided that X and Y are not both O;

provided that when X is O, R^lb is not OH; .

provided that when Y is O, and n is 0, R⁸ is not OH; and provided that when R⁶ and R⁷ together are oxo, one R², R³, R⁴, and R³ is methoxy or ethoxy, and the other of R², R³, R⁴, and R³ is H, then Q is not unsubstituted pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl.

In one group of embodiments, provided is a method wherein z is 0. In another group of embodiments, z is 1. In yet another group of embodiments, z is 2. In still another group ofembodiments, z is 3. In another group of embodiments, z is 4. In yet another group of embodiments, z is 5. In still another group of embodiments, z is 6.

Γ. Examples

The following examples are offered to illustrate, but not to lîmit, the claimed invention.

PREPARA TIVE EXAMPLES

The starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in référencés such as Fieser and Fieser’s Reagents for Organic Synthesis; Wiley & Sons: New York, 1967-2004, Volumes 1-22; Rodd's Chemistry of Carbon Compounds, Elsevier Science Publishers, 19S9, Volumes 1-5 and Supplémentais; and Organic Reactions, Wiley & Sons: New York, 2005, Volumes 1-65.

The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.

Unless specified to the contrary, the reactions described herein preferably are conducted under an inert atmosphère at atmospheric pressure at a reaction température range of from about -7S°C to about 150°C, more preferably from about 0°C to about 125°C, and most preferably and conveniently at about room (or ambient) température, e.g., about 20°C to about 75°C.

Referring to the examples that follow, compounds of the présent invention were synthesized using the methods described herein, or other methods known in the art.

Example 1. Préparation of2-(imidazo[l,5-a]pyridin~8-ylmethoxy)~5-methoxybenzaldehyde

Step 1:

COjEt

CO₂Et i 0'

To a cold solution of 3-ethoxycarbonylpyridine (25 g, 165.4 mmol, 1 eq) in DCM was slowly added mCPBA (70% wt, 198.5 mmol) and the reaction mixture was stirred at rt ovemight.Reaction was cooled and diluted with DCM and then neutralized with slow addition of sat. NaHCOj.Aqueous layer was washed with DCM (3X) and the combined organic layer was dried and evaporated to give a residue, which was purified by column chromatography (EtOAc/ MeOH) to give 3-ethoxycarbonylpyridine N-oxide (13.6 g). MS: exact mass calculated for CgHjNOj, 167.06; m/z found, 168 [M+H]⁺.

Step 2:

Compound A, Major

Compound B, Minor

To a solution of 3-ethoxycarbonylpyridine N-oxide in 330 mL of DCM were added trimethylsilyl cyanide (TMSCN) (11.0 g, 65.9 mmol, 1.0 eq) and dimethylcarbamoyl chloride (7.1 g, 65.9 mmol, 1.0 eq) and the reaction mixture was stirred at rt for 2 days. Then 10% KîCOj was slowly added to make the reaction mixture basic.Organic layer was separated, dried and evaporated to provide the crude, which was purified by column chromatography to provide compounds A (5.7 g) and B (3.5 g).

Steps 3 and 4:

γΧ^ΝΗ₂·Ηα CO₂Et

To a solution of ethyl 2-cyano-3-pyridinecarboxylate (2.5 g) and conc. HCl (5 mL) in 150 mL éthanol was added 10% Pd/C (wet, 250 mg) and the reaction mixture was hydrogenated using a hydrogen balloon and stirred for 12 h. The reaction was filtered through celite and éthanol was evaporated to give ethyl 2-(aminomethyl)-3pyridinecarboxylate HCl as a white solid which was used in the next step without further purification.

A mixture of 44.8 mL of acetic anhydride and 19.2 mL of formic acid was heated in a 50-60 °C oil bath température for 3 h and then cooled to rt to give formic-acetic anhydride, which was then slowly added to the solid ethyl 2-(aminomethyl)-3-pyridinecarboxylate HCl and then stirred at rt for 8 h. Excess reagent was evaporated to give a residue, which was neutralized by very slow addition of sat. NaHCOj solution. Solution was extracted with DCM, dried and evaporated to provide ethyl imidazo[l,5-a]pyridine-8-carboxylate as a yellow solid (crude weight 2.7 g). MS: exact mass calculated for CtoHtoN₂0₂, 190.07; m/z found, 191 [M+H]⁺.

Steps 5 and 6:

To a cold solution of lithium aluminum hydride (1.62 g, 42,4 mmol, 4.0 eq) in THF (50 mL) was added the crude ethyl imidazo[l,5-a]pyridine-8-carboxylate (2.7 g, 14.2 mmol, 1.0 eq) and the reaction mixture was heated at reflux for 2 h. The reaction was cooled and water (1.7 mL), 15% NaOH (1.7 mL) and water (5.1 mL) were slowly added.Solution was diluted with excess EtOAc and stirred at rt for 30 min. The solution was filtered and the solid was washed with ethyl acetate. Organic layers were combined, dried and solvent was removed to give crude imidazo[l,5-a]pyridine-8-methanol, which was purified by column chromatography (EtOAc/ Hexane). MS: exact mass calculated for CgHgtyO, 148.06; m/z found, 149 [M+H]⁺.

To a solution of imidazo[l,5-a]pyridine-8-methanol (800 mg) in chloroform (50 mL) was slowly added thionyl chloride (10 mL) and the reaction mixture was stirred at rt for

h. Chloroform was removed and the residue was then taken in toluene and toluene was evaporated (3x) to give a solid, which was used in the next step without further purification. MS: exact mass calculated for CgHîCINî, 166.03; m/z found, 167 [M+H]⁺.

Step 7:

O Me

To a solution of chloride (1.25 mmol, 1.0 eq), and phénol (1.25 mmol, 1.0 eq) in

DMF (10 mL) was added K2CO3 (3.0 eq) and the reaction mixture was heated at 80-90 °C for 5 h. Solvent was removed and the residue was purified by column chromatography (EtOAc/ MeOH).NMR (400 MHz, CDCI3): 5 3.82 (s, 3H), 5.45 (s, 2H), 6.58 (m, IH), 6.81 (m, IH),

7.03 (s, IH), 7.12 (m, IH), 7.35 (m, IH), 7.50 (s, IH), 7.95 (m, IH), 8.18 (s, IH), 10.58 (s,

IH); MS: exact mass calculated for C16H14N2O3,282.10; m/z found, 283 [M+H]⁺.

Example 2. Préparation of2-(imidazo[l,5-a]pyridin-8-ylmethoxy)~4-methoxybenzaldehyde

The title compound was prepared usîng 2-hydroxy-4-methoxybenzaldehyde in a similar manner as in Example 1. NMR (400 MHz, CDCI3): δ 3.85 (s, 3H), 5.50 (s, 2H), 6.506.60 (m, 3H), 6.88 (s, IH), 7.48 (s, IH), 7.88 (m, 2H), 8.18 (s, IH), 10.58 (s, IH); MS: exact mass calculated for C16H14N2O3,282.10; m/z found, 283 [M+H]⁺.

Example 3. Préparation of 2-(imidazo[l,5-a]pyridin-6-ylmethoxy)-5-methoxybenzaldehyde

OMe

Steps 1 and 2:

CO₂Et

To a solution of ethyl 6-cyano-3-pyridinecarboxylate (3.75 g) and conc. HCl (7.5 mL) în 225 mL éthanol was added 10% Pd/C (wet, 375 mg) and the reaction mixture was hydrogenated using hydrogen balloon and stirred for 12 h. Solution was fîltered through celite and éthanol was evaporated to give ethyl 6-(aminomethyl)-3-pyridinecarboxylate HCl as a white solid, which was used in the next step without further purification.

A mixture of 67.2 mL of acetic anhydride and 28.8 mL of formic acid was heated at 50-60 °C oil bath température for 3 h and then cooled to rt to give formic-acetic anhydride, which was then slowly added into the solid ethyl 2-(aminomethyl)-3-pyridinecarboxylate HCI and then stirred at rt for 8 h. Excess reagent was evaporated to give a residue, which was neutralized by very slow addition of sat NaHCOj solution. Solution was extracted with DCM, dried and evaporated to provide imidazo[l,5-a]pyridine as a yellow solid.MS: exact mass calculated for CjoHjoNîOj, 190.07; m/z found, 191 [M+H]⁺.

Steps 3 and 4:

To a cold solution of lithium aluminum hydride (1.0 g, 26.3 mmol, 2.0 eq) in THF (40 mL) was added the crude ethyl imidazopyridine carboxyiate (2.5 g, 13.2 mmol, 1.0 eq) and the réaction mixture was stirred at rt for 2 h. Reaction was cooled and water (1.7 mL), 15% NaOH (1.7 mL) and water (5.1 mL) were slowly added.Solution was next diluted with excess EtOAc and stirred at rt for 30 min. The solution was filtered and the solid was washed with ethyl acetate. Organic layers were combined, dried and solvent was removed to give crude imidazo[l,5-a]pyridine-8-methanol, which was purified by column chromatography (EtOAc/ Hexane). MS: exact mass calculated for CgHgNiO, 148.06; m/z found, 149 [M+H] + »

To a solution of imidazopyridine methanol (700 mg, 4.7 mmol, 1.0 eq) in chloroform (20 mL) was slowly added thionyl chloride (1.7 mL) and the reaction mixture was stirred at rt for 8 h. Chloroform was removed and the residue was then taken up in toluene. Toluene was evaporated (3x) to give a solid (550 mg), which was used in the next step without further purification.

Step 5:

OH

OHC

OMe

N +

HCl

K₂CO₃

DMF

To a solution of chloride (1.25 mmol, 1.0 eq), and phénol (1.25 mmol, 1.0 eq) in DMF (10 mL) was added K2CO3 (3.0 eq) and the reaction mixture was heated at 80-90 °C for 5 h. Solvent was removed and the residue was purified by column chromatography (EtOAc/ MeOHJ.MS: exact mass calculated for CiéHhNzOj, 282.10; m/z found, 283 [M+H]⁺.

Example 4. Préparation of2-(imidazo[l_t5-a]pyridin-6-ylmethoxy)-4-methoxybenzaldehyde

The tïtle compound was prepared using 2-hydroxy-4-methoxybenzaldehyde in a similar manner as in Example 3.

Example 5. Préparation of methyl imidazo[l,2-a]pyridine-8-carboxylate

CO₂CH₃

To a solution of methyl 2-amino-pyridine-3-carboxylate (5 g, 35 mmol, 1.0 eq) in éthanol (250 mL) was added NaHCOj (5.08 g) and chloroacetaldehyde in water (35 mL of 45% in water, 148 mmol, 4.5 eq). The reaction mixture was heated at reflux for 18 h. Solvent was removed and the residue was basified with Na₂CO₃ and then extracted with DCM. Organic layers were combined and evaporated to give a residue, which was purified by column to give the titled compound.

Example 6. Préparation ofimidazo[l,2-a]pyridin-8-ylmethanol

To a cold solution ofmethyl imidazo[l,2-a]pyridine-8-carboxylatee (5.55 g, 31.53 mmol, 1 eq) in THF (100 mL) was added LAH in ether (1 M solution in ether, 4 equiv.) and then stirred at rt for 6 h. The reaction mixture was cooled to 0 °C and quenched with water/ 15% NaOH/ water. Reaction mixture was diluted with ethyl acetate and stirred at room température for 15 min and then fîltered. The solid was washed with éthanol and the organic layers were combined, dried and evaporated to give the alcohol, which was purified by column chromatography to yield the desired product in 40% yield.

Example 7. Préparation of8-(chloromethyl)imidazo[l,2-a]pyridine

A mixture of imidazo[l,2-a]pyridin-8-ylmethanol (800 mg) and excess thionyl chloride was stirred at 70-80 °C for 8 h. Excess thionyl chloride was removed under vacuum. The residue was then diluted with toluene and evaporated. This procedure was repeated 3 times.

Example 8. Préparation of2-(imidazo[l,2-a]pyridin-8-ylmethoxy)-5-methoxybenzaldehyde

θχ

To a solution of the crude 8-(chloromethyl)imidazo[l,2-a]pyridine (6.8 mmol, 1 eq) and 2-hydroxy-5-methoxybenzaldehyde (1.3 g, 8.1 mmol, 1.2 eq) in DMF (20 mL) was added potassium carbonate (2.8 g, 20.4 mmol, 3 eq) and the reaction mixture was heated at 85-90 °C for 5 h. DMF was removed under vacuum and the residue was taken in ethyl acetate and filtered. The solid was washed with additional ethyl acetate, and then dried and evaporated to give the crude, which was purified by column chromatography (EtOAc/ Hexane) to yield the desired compound in 45% yield. NMR (400 MHz, CDCI3): δ 3.80 (s,

3H), 5.60 (s, 2H), 6.85 (d, 1H), 7.12 (d, 2H), 7.36(m, 2H), 7.66 (m, 2H), 8.14 (m, 1H), 10.58 (s, 1H); MS: exact mass calculated for C16H14N2O3,282.10; m/z found, 283 [M+H]⁺.

Example 9. Préparation of2-(imidazo[l,2-a]pyridin-8~ylmethoxy)~4-methoxybenzaldehyde

The title compound was prepared using 2-hydroxy-4-methoxybenzaldehyde in a similar manner as in Example 3. NMR (400 MHz, CDCb): δ 3.88 (s, 3H), 5.65 (s, 2H), 6.58 (m, 1H), 6.68 (s, 1H), 6.88 (m, 1H), 7.42 (m, 1H), 7.66 (m, 2H), 7.83 (m, 1H), 8.14 (m, IH), 10.45 (s, 1 H); MS: exact mass calculated for C16H14N2O3,282.10; m/z found, 283 [M+H]⁺.

Example 10. Préparation of 5-methoxy-2-((l-methyl-lH-indazol-4-yl)methoxy)benzaldehyde (Compound 115)

Step 1 :

To a mixture of l-methyl-lH-indazole-4-carbaIdehyde (180 mg, 1.12 mol) in THF (10 mL) was added NaBH₄ (85 mg, 2.24 mmol) at rt. The reaction mixture was stirred at rt for 1 h, acidified to pH 3, and extracted with EtOAc. The combined organic layer was washed with saturated sodium bicarbonate solution and brine, dried over Na₂SO4, filtered,

10. and concentrated to gi ve a crude solid (191 mg), which was used for next step without further purification.

Step 2:

-bo	SOCI₂	\
DCM
hct		cr

To (l-methyl-lH-indazol-4-yl)methanol (191 mg) in DCM ( 5 mL) was added

SOC1₂ (2 mL) at rt. The reaction mixture was stirred at rt for 4 h and concentrated to dryness. The crude solid was suspended ïn toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give an off-white solid (210 mg), which was used for next step without further purification.

Step 3:

A mixture of 2-hydroxy-5-methoxybenzaldehyde (170 mg, 1.12 mmol), 4(chloromethyl)-l-methyl-lH-indazole (1.12 mmol), and K₂COj (618 mg, 4.48 mmol) was reflux in CH3CN (20 mL) for 2 h. The mixture was filtered and the solid was washed with

DCM. The filtrate was concentrated and purified on silica gel using a mixture of EtOAc and MeOH as eluent to give 5-methoxy-2-((l-methyl-lH-îndazol-4-yl)methoxy)benzaldehyde (215 mg, 81% for three steps) as a white solid. *H NMR (400 MHz; DMSO)5= 10.39 (s, 1 H), 8.20 (d, 1 H), 7.63 (d, 1 H) 7.36-7.64 (m, 2 H), 7.23-7.29 (m, 2 H), 7.18 (d, 1 H), 5.58 (s, 2 H), 4.06 (s, 3 H), 3.34 (s, 3 H). LRMS (M+H⁴) m/z 297.1.

Example 11. Préparation of2-((lH-indazol-4-yl)methoxy)-5~methoxybenzaldehyde

Step 1:

To a mixture of 4-(chloromethyl)-lH-indazole (1.0 g, 6.0 mol) in DCM (20 mL) was added (Boc)₂O (1.96 g, 9.0 mmol) and DMAP (dimethylamino pyridine 67.2 mg, 0.6 mmol) at rt. The reaction mixture was stirred at rt for 1 h, concentrated, and purified on silica gel to give tert-butyl 4-(chloromethyl)-lH-indazole-l-carboxylate (1.4 g, 88%) as an a colorless oil.

Step 2:

Boc	OH /0	Boc 5o Ό /
	K₂CO_3[ CH₃CN	çK
		Γ °x

A mixture of 2-hydroxy-5-methoxybenzaldehyde (46 mg, 0.3 mmol), tert-butyl 4(chloromethyl)-lH-indazole-l-carboxylate (80 mg, 0.3 mmol), and K2CO3 (166 mg, 1.2 mmol) in DMF (1.0 mL) was heated at 80 °C for 2 h. The mixture was fîltered and the solid was washed with DCM. The filtrate was concentrated and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give tert-butyl 4-((2-formyl-4methoxyphenoxy)methyl)-lH-indazole-l-carboxylate (88 mg, 77%) as a colorless oil.

Step 3:

To tert-butyl 4-((2-formyl-4-methoxyphenoxy)methyl)-l H-indazole-1 -carboxylate (88 mg, 0.23 mmol) in DCM (5.0 mL) was added TFA (2.0 mL). The mixture was stirred at rt for 2 h and concentrated. The crude was purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 2-((1 H-indazol-4-yl)methoxy)-5-methoxybenzaldehyde (50 mg, 15 77%) as a white solid. 'H NMR (400 MHz; CDClj) δ= 10.53 (s, 1 H), 8.23 (s, 1 H), 7.54 (d, 1

H) 7.43 (t, 1 H), 7.38 (d, 1 H), 7.25 (d, 1 H), 7.08-7.15 (m, 2 H), 5.51 (s, 2 H), 3.82 (s, 3 H). LRMS (M+H*) m/z 283.1.

Example 12. Préparation of3~(imidazo[l,2~a]pyridin-8-ylmethyl)-l,3· dihydroisobenzofuran-l-ol

Step 1:

To a solution of methyl imidazo[l,2-a]pyridine-8-carboxylate (1.76 g, 10 mmol) in toluene was added DIBAL (1M/THF, 20 ml) at -78 °C dropwise. The mixture was stirred at 78 °C for 1 h, quenched with MeOH (2 mL) and saturated NH4CI solution (50 mL) and warmed up to rt. The mixture was continued to stir at rt for 1 h and diluted with DCM (60 mL). The aqueous layer was extracted with DCM (60 mL) twice. The combined organic layer was dried over MgSO4 and concentrate. The residue was purified on silica gel with 10 % MeOH/DCM to give imîdazo[l_f2-a]pyridine-8-caibaldehyde (0.8g, 55%). LRMS (M+H⁴) m/z 147.1.

Step 2:

O ^ηΆ _

NaOMe, MeSO₃H MeOH

To a solution of sodium methoxîde (5.4 M, 4.8 mL) in MeOH (20 mL) was added diethyl phosphite (3.31 g, 24 mmol) at 0 °C followed by addition of2-formylbenzoic acid (3.0 g, 20 mmol) portion-wise over a period of 20 min. The resulting mixture was warmed up to rt and continued to stir for 2 h. Methanesulphonîc acid (2.69 g, 28 mmol, 1.4 equiv.) was added to the above mixture over a period of 30 min. The reaction mixture was stirred for 30 min and concentrated to remove most of the MeOH. The residue was partîtioned between DCM (100 mL) and water (50 mL). The aqueous layer was extracted DCM twice. The combined organic layer was dried overNa₂SO4 and concentrated to give dimethyl 3-oxo-l,3dihydroisobenzofuran-l-ylphosphonate (4.6 g, 90%). LRMS (M+H⁴) m/z 257.1.

Step 3:

To a solution of dimethyl 3-oxo-l ,3-dihydroisobenzofuran-I -ylphosphonate (610 * mg, 2.4 mmol), imidazo[l,2-a]pyridine-8-carbaldehyde (350 mg, 2.4 mmol, 1 equiv.) in THF ( 5 mL) was added EtjN (0.33 mL 2.4 mmol). The mixture was stirred at rt for 48 h. The précipitation was filtered off and washed with EtOAc. The filtrate was concentrated to give 3-(imidazo[l,2-a]pyridin-8-ylmethylene)isobenzofuran-l(3H)-one(400ing, 64%) as a yellow solid, Small crude sample (—20 mg ) was purified on RP-HPLC with CHjCN and water as eluent to separated the E/Z isomers (10 mg, 7 mg). *H NMR(400 MHz, CDjOD) Z-form: 6= 8.52 (d, I H), 7.95-7.91 (m, 2 H), 7.62-7.54 (m, 4 H), 7.52-7.48 (m, 1 H), 7.09 (s, 1 H), 7.04 (t, 1 H) E-form: δ= 8.38 (d, 1 H), 8.15 (d, H), 8.05 (d, 1 H), 7.95 (d, 1 H), 7.90-7.84 (m, 2 H), 7.67 (t, 1 H), 7.64 (s, 1 H), 7.33 (s, 1 H), δ 7.05 (t, 1 H). LRMS (M+H⁴) m/z 263.1

Step 4:

To a solution of 3-(imidazo[l,2-a]pyridin-8-ylmethylene)isobenzofuran-l(3H)-one (180 mg, 0.69 mmol) in EtOAc (12 mL) was added 10% Pd/C (110 mg). The mixture was stirred under a hydrogen balloon ovemight. The catalyst was filtered off and the filtrate was concentrated and purified on silica gel with 10% MeOH/DCM as eluent to give 3(imidazo[l,2-a]pyridin-8-ylmethyl)isobenzofuran-l(3H)-one (140 mg, 78%). *H NMR (400 MHz, CD₃OD) δ= 8.37 (d, IH), δ 7.88 (s, 1 H), 7.83 (d, 1 H), 7.74-7.63 (m, 2 H), 7.60-7.53 (m, 2 H), δ 7.22 (d.I H), 6.86 (t, 1 H), 6.04 (dd, 1 H), 3.76 (dd, I H), 3.24 (dd, 1 H). ). LRMS (M+H⁴) m/z 265.1

Step 5:

Το a solution of 3-(imidazo[l,2-a]pyridin-8-ylmethyl)isobcnzofuran-l(3H)-one (80 mg, 0.3 mmol) in DCM (6 mL) at -78 °C, was added lithium triethyl borohydride (1M/THF, 0.3 mL) dropwise. The reaction mixture was stirred at -78 °C for 30 min, diluted with DCM 5 (V10 mL), and quenched with MeOH (1 mL) and 5% HCl (2 mL). The mixture was warmed up to rt and stirred for 1 h. The solvents were removed and the residue was purified on RPHPLC using CHjCN and water as eluent to give 3-(imidazo[l,2-a]pyridin-8-ylmethyl)-l,3dihydroisobenzofuran-l-ol (20 mg, 25%). *H NMR(400 MHz, CD₃OD) δ= 8.56 (t, 1 H), 8.97(d, 1 H), 7.74 (s, 1 H), 7.45-7.32 (m, 5 H), 7.07-7.00 (m, 1H), 6.38-6.30 (m, 1 H), 5.8410 5.80(m, 0.5 H), 5.56 (dd, 0.5 H), 3.69 (t, 0.5 H), 3.65 (t, 0.5 H), 3.26 (dd, 0.5 H), 3.13 (dd, 0.5

H). LRMS (M+H⁴) m/z 267.1.

Example 13. Préparation of 5firmdazo[l,2-a]pyridin-8-ylmethoxy)-2methoxyibenzaldehyde.

Stepl:

To a mixture of 6-methoxyphen-3-ol (25 g, 0.2 mol) and K2CO3 (82.8 g, 0.6 mol) in DMF (250 mL) is added bromomethyl methyl ether (30 g, 0.24 mmol) slowly at rt for a period of lh. The reaction mixture is filtered and the filtrate is concentrated. The residue is purified on silica gel with 25% EtOAc/hexanesas eluent to give 2-methoxy-5(methoxymethoxy)benzene.

Step 2:

To a solution of 2-methoxy-5-(methoxymethoxy)benzene (20 g, 0.1 2 mol) in THF îs added diisopropylamine (0.24 g, 2.4 mmol). The solution is cooled to -40 °C followed by addition of MeLi (3M/THF, 72mL, 0.216 mol) slowly. The resulting mixture is warmed to 0 °C, stirred at 0 °C for 3 h, cooled back down to -40 °C and added N-formylpiperidîne (24mL, 0.216mol). After stirring at -40 °C for 2 h, the mixture is quenched with a mixed solution of HCl (37%, 120 mL) and THF (250 mL). The température is then raised to rt and diluted with water (200 mL) and EtOAc (200 mL). The pH of the mixture is adjusted to 8-9 with solid K₂COj and extracted with EtOAc (300 mL) twice. The organic layer is combined, dried over Na₂SO₄, and concentrated. The residue is purified on silica gel with 25%EtOAc/hexanes as eluent to give 2-methoxy-5-(methoxymethoxy)benzaldehyde.

Step 3:

To a solution of 2-methoxy-5-(methoxymethoxy)benzaIdehyde (10 g, 0.05 mol) in THF (100 mL) was added 3 N HCl (150 mL). The reaction was stirred at 50 °C for 30 min, cooled to rt, and diluted with water (100 mL). The mixture was neutralized to pH 7-8 and extracted with EtOAc (200 mL) three times. The organic layer was dried over Na₂SO₄ and concentrated to give 5-hydroxy-2-methoxybenzaldehyde.

Step 4:

A mixture of 5-hydroxy-2-methoxybenzaldehyde (723.6 mg, 4.7 mmol), 8(chloromethyl)-imidazol[l,2-a] pyridine (785 mg, 4.7 mmol), and K₂COj (1.9 g, 14.1 mmol) in DMF (20 mL) was heated at microwave reactor at 125 °C for 15 min. The mixture was filtered and concentrated. The residue was purified on silica gel (50-100% EtOAc in hexanes) to give 5-(imidazo[l,2-a]pyridin-8-ylmethoxy)-2-methoxybenzaldehyde.

The compounds Examples 14-16 were prepared according to the procedure described in Example 13.

Example 14. Préparation of2-(imidazo[l,2-a]pyridin-2-ylmethoxy)-5-méthoxybenzaldéhyde (Compound 5.) ’HNMR (400 MHz, DMSO) δ 10.39 (s, IH), 8.53 (d, 6.8 Hz, IH), 8.06 (s, IH),

7.54 (d, 9.1 Hz, IH), 7.42 (d, J= 9.1 Hz, IH), 7.29-7.22 (m, 2H), 7.17 (d, 3.3 Hz,

IH), 6.90 (t, J= 6.8 Hz, IH), 5.35 (s, 2H), 3.76 (s, 3H).

Example 15. Préparation of 5-methoxy-2-(quinolin-5-ylmethoxy)benzaldehyde (Compound 10).

*H NMR (400 MHz, CDClj) δ 9.09 (s, IH), 7.73 (dd, 4.0,1.3 Hz, IH), 7.19 (d, J = 8.4 Hz, IH), 6.92 (d, 8.4 Hz, IH), 6.48 (t, J= 8.4 Hz,, IH), 6.40 (d, J~ 6.9 Hz, IH),

6.24 (dd, y = 8.5,4.2 Hz, IH), 6.10 (d, J = 2.6 Hz, IH), 5.95 - 5.85 (m, 2H), 4.32 (s, 2H), 2.56 (s, 3H).

Example 16. Préparation of 5-methoxy-2-((8-methylimidazo[1,2-a]pyridin~2· yl)methoxy)benzaldehyde (Compound 24).

'HNMR(400MHz, CDjCN)ô 10.32 (s, 1H),8.O1 (d,J=6.8Hz, lH),7.68(s, IH), 7.19 (d, 9.0 Hz, IH), 7.13 (d, J= 3.2 Hz, IH), 7.08 (dd, J= 9.0,3.3 Hz, IH), 6.90 (td, J = 6.8,1.2 H IH), 6.62 (t, J= 6.s Hz, IH), 5.21 (s, 2H), 3.67 (s, 3H), 2.39 (s, 3H).

Example 17. Préparation of2-hydroxy-6-((2-(l-isopropyl-1 H-pyrazol-5-yl)pyridin~3yl)methoxy)benzaldehyde (Compound 43).

OH

A mixture of 2,6-dihydroxybenzaldehyde (1.96 g, 14.2 mmol, 2 eq.) and CS2CO3 (7.5 g, 21.3 mmol, 3 eq.) in DMF (180 mL) was stirred at rt for 30 min. To this mixture was added 3-(chloromethyl)-2-(l-isopropyl-lH-pyrazol-5-yl)pyridine hydrochloride (1.93 g, 7.1 mmol, leq.) at rt. The mixture was continued to stir at rt O/N, filtered, concentrated and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 2-hydroxy-6((2-(1 -isopropyl-1 H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (920 mg, 37%) as a pale yellowoil. 'HNMR (400MHz, CDC1₃) δ 11.96 (s, IH), 10.40 (s, IH), 8.77(dd,7= 4.8,

1.5 Hz, IH), 8.00 (d,7= 7.8 Hz, IH), 7.63 (d,7= 1.8 Hz, IH), 7.49-7.34 (m, 2H), 6.59 (d,7 = 8.5 Hz, IH), 6.37 (d,7= 1.8 Hz, IH), 6.29 (d,7=8.2 Hz, IH), 5.10(s, 2H), 4.67 (sep,7= 6.7 Hz, IH), 1.50 (d,7= 6.6 Hz, 6H). LRMS (M+H⁴) m/z 338.1

Example 18. Prépara tion of 2-hydroxy-6-((2-(1 -isopropy!-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde (Compound 43).

OH

A mixture of 2,6-dihydroxybenzaldehyde (1.58 g, 11.47 mmol, 2 eq.) and K2CO3 (2.4 g, 17.22 mmol, 3 eq.) in DMF (150 mL) was stirred at rt for 10 min. To this mixture was added 3-(chloromethyl)-2-(l -isopropyl-1 H-pyrazol-5-yl)pyridine hydrochloride (1.56 g, 5.74 mmol, leq.) at rt. The mixture was heated at 50°C for 2 h, filtered, concentrated and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 2-hydroxy-6-((2-(lisopropyl-1 H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (1.71 g, 88%) as a pale yellowsolid. *H NMR (400 MHz,CDClj) δ 11.96 (s, IH), 10.40 (s, IH), 8.77 (dd,J= 4.8,

1.5 Hz, IH), 8.00 (d, J= 7.8 Hz, IH), 7.63 (d, J= 1.8 Hz, IH), 7.49-7.34 (m, 2H), 6.59 (d, J = 8.5 Hz, IH), 6.37 (d, 1.8 Hz, IH), 6.29 (d, J= 8.2 Hz, IH), 5.10(s, 2H), 4.67 (sep, J=

6.7 Hz, IH), 1.50 (d, J= 6.6 Hz, 6H). LRMS (M+H*) m/z 338.1

Example 19. Préparation of5-((2-(2H-tetrazol-5-yl)pyridin~3-yl)methoxy)-2methoxybenzaldehyde.

Step 1:

To a mixture of 5-((2-bromopyridin-3-yl)methoxy)-2-methoxybenzaldehyde (100 mg, 0.31 mmol, 1 equiv), Zn (CN)₂ (71 mg, 0.62 mmol, 2.0 equiv), Pd(PPh₃)₄ (72 mg, 0.06 mmol, 0.2 equiv) in a 5 mL microwave tube is added DMF (2 mL). The mixture is heated 15 min at 125 °C in a microwave reactor. The solid is filtered off and the filtrate is concentrated to dryness.The crude was purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 3-((4-formyl-6-methoxyphen-3-yloxy)methyl)picolinonitrile.

Step 2:

Το TEA hydrochloride sait (123 mg, 0.89 mmol, 4 equiv.) and 3-((4-formyl-6methoxyphen-3-yloxy)methyl)picolinonitriIe (70 mg, 0.26 mmol, 1 equiv.) in chlorobenzene (5.0 mL) is added NaNj (48 mg, 0.89 mmol, 4 equiv.) at rt. The mixture is heated to 110 °C for 2 h, cooled to rt, and added water (5.0 mL). The precipitate is filtered and washed with EtOAc and water and dried under high vacuo to give 5-((2-(2H-tetrazol-5-yl)phen-3yl)methoxy)-2-methoxyisonicotinaldehyde.

The compounds in Examples 20 and 21 were prepared according to the procedure described in Example 19.

Example 20. Préparation of2-((3-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenza!dehyde (Compound 44).

. *H NMR (400 MHz, CDjCN) δ 11.95 (s, 1H), 10.45 (s, 1H), 8.17 (s, 1H), 8.05 (d, J = 7.7 Hz, 1 H), 7.69 (d, J = 7.8 Hz, 1 H), 7.62 (t, J = 7.7 Hz, 1 H), 7.49 (t, J = 8.4 Hz, I H), 6.62 (d, 8.3 Hz, 1H), 6.54 (d, 8.5 Hz, 1H), 5.30 (s, 2H).

Example 21.-Préparation of2-((4-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde (Compound 45).

*H NMR (400 MHz, DMSO) δ 11.77 (s, 1H), 10.40 (s, 1H), 8.06 (d, 8.2 Hz,

2H), 7.69 (d, J= 8.0 Hz, 2H), 7.54 (t, J= 8.4 Hz, 1H), 6.73 (d, 8.4 Hz, 1H), 6.56 (d, J=

8.5 Hz, 1H), 5.33 (s, 2H).

Example 22. Préparation of 5-((4-formyl-6-methoxyphen-3-yloxy)methyl)nicotinic acid.

Step 1:

A mixture of 5-hydroxy-2-methoxÿbenzaldehyde (352 mg, 2.29 mmol, 1 eq.), methyl 5-(chloromethyl)nicotinatehydrochloride (506 mg, 2.29 mmol, 1 eq.), and K2CO3 (1.26 g, 9.16 mmol, 4 eq.) in DMF (8.0 mL) is heated at 60 °C for 3 h. The mixture is cooled and added into water (50 mL) dropwise. The precipitate is filtered, washed with water, and dried to give methyl 5-((4-formyl-6-methoxyphen-3-yloxy)methyl)nicotinate.

Step 2:

O _ A		O
U ¹		V
or 1	NaOH (3 N)	O^J
-		1
J ^υ	MeOH/THF
		T

To 5-((4-formyl-6-methoxyphen-3-yloxy)methyl)nicotinate (96 mg, 0.32 mmol, 1 eq.) in a mixture of MeOH/THF (1/3,8.0 mL) is added NaOH (3 N, 1.7 mL, 5.1 mmol, 16 eq.). The mixture is stirred at rt for 2 h, acidified to pH 3, extracted with EtOAc (3 x 20 mL). The combined organic layers are dried over Na₂SO.| and concentrated to give 5-((4-formyl-6methoxypyridin-3-yloxy)methyl)nicotinic acid.

The compounds in Examples 23-25 were prepared according to the procedure described in Example 22.

Example 23. Préparation of methyl 4-((2~formylphenoxy)methyl)benzoate (Compound 46).

‘H NMR (400 MHz, CDClj) δ 10.51 (s, IH), 8.01 (d, 8.3 Hz, 2H), 7.81 (dd, J=

7.7, 1.8 Hz, IH), 7.51 -7.40(m, 3H), 7.00(t, J= 7.5 Hz, IH), 6.94 (d, J= 8.4 Hz, IH), 5.19 (s, 2H), 3.86 (s, 3H).

Example 24. Préparation of 4-((2-formylphenoxy)methyl)benzoîc acid (Compound 47).

*H NMR (400 MHz, CDClj) δ 10.52 (s, IH), 8.09 (d, J= 8.2 Hz, 2H), 7.81 (dd,

7.7,1.6 Hz, IH), 7.53-7.43 (m,3H), 7.01 (t, 7.5 Hz, IH), 6.95 (d, J= 8.4 Hz, IH), 5.21 (s, 2H).

Example 25. Préparation of methyl 3-((2-formylphenoxy)methyl)benzoate (Compound 48).

'H NMR (400 MHz, CDClj) δ 10.58 (s, IH), 8.14 (s, IH), 8.06 (d, J=7.8 Hz, IH), 7.90 (dd, 7.7,1.8 Hz, 1H),7.69 (d,J=7.7 Hz, IH), 7.60-7.48 (m, 2H), 7.08(dd,J= 14.4,7.9 Hz, 2H), 5.26 (s, 2H), 3.96 (s, 3H).

Example 26. Préparation of 5-hydroxy-2-methoxybenzaldehyde.

Step 1:

To a solution of 6-methoxyphen-3-ol (20 g, 0.16 mol, 1 eq.) in DMF (200 mL) was added NaH (60% in minerai oil; 9.6 g, 0.24 mol, 1.5 eq.) at 0-5 °C portion-wise. Upon the completîon of addition, the mixture was continued to stïr at 0-5 °C for 15 min, added chloromethyl methyl ether (15.5 g, 0.19 mol, 1.2 eq.), stirred at 0-5 °C for another 20 min, and quenched with NH₄Cl(_Mt) solution. The aqueous layer was extracted with EtOAc (3 x 100 mL) and the combined organic layers were washed with water and brine, dried over Na₂SO₄, concentrated, and purified on silica gel using 25% EtOAc/hexanes as eluent to give 2-methoxy-5-(methoxymethoxy)benzene (24.1 g, 89.3%) as a colorless oil.

Step 2:

To a mixture of 2-methoxy-5-(methoxymethoxy)benzene (30 g, 0.178 mol, 1 eq.) and diisopropylamine (507 uL, 3.6 mmol, 0.02 eq.) in THF (500 mL) was added methyl lithium (1.6 M/THF, 200 mL, 0.32 mol, 1.8 eq.) at -40 °C.Upon the completîon of addition, the mixture was warmed to 0 °C, continued to stir at 0 °C for 3 h, cooled back down to -40 °C and added DMF (24.7 mL, 0.32 mol, 1.8 eq.) slowly. The mixture was then stirred at -40 °C for 1 h, quenched with a mixture of HCl (12 N, 120 mL) and THF (280 mL), warmed to rt, and added water (200 mL). The pH ofthe mixture was adjusted to pH 8-9 with solid K2CO3. The aqueous layer was extracted with EtOAc (300 mL) twice. The combined organic layers were dried over Na2SO₄ and concentrated to give 2-methoxy-5(methoxymethoxy)benzaldehyde (33.5 g, 95.7%) as a brown solid, which was used for next step without further purification. 'H NMR (400 MHz; CD3OD) 7.90 (s, 1 H), 6.92 (s, 1 H), 5.64 (s, 1 H), 5.20 (s, 2 H), 3.84 (s, 3 H), 3.48 (s, 3 H). LRMS (M+H*) m/z 198.1

Step 3:

To a solution of 2-methoxy-5-(methoxymethoxy)benzaldehyde (33.5 g, 0.17 mol, 1 eq.) in THF (150 mL) was added HCl (3 N, 250 mL, 4.4 eq.). The reaction was stirred at 50 °C for 1 h, cooled to rt, and diluted with water (500 mL). The mixture was neutralized to pH 7-8 with solid K₂COj. The pale yellow solid was collected, washed with water, and dried to give 5-hydroxy-2-methoxybenzaldehyde (17.9 g, 74.6%) as a pale yellow solid. *H NMR (400 MHz; DMSO) δ= 10.31 (s, 1 H), 8.03 (s, 1 H), 6.89 (s, 1 H), 3.80 (s, 3 H). LRMS (M+H⁺) m/z 154.0.

Example 27. Préparation of5-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)-2methoxybenzaldehyde (Compound 150).

Step 1:

O

1)TEA Bu'O^CI

NaBH/THF

To a solution of 2-bromonicotinic acid (4.0 g, 20 mmol) and triethylamine (3.34 mL, 24 mmol, 1.2 eq.) in THF (100 mL) was added f-butyl chloroformate (3.12 mL, 24 mmol, 1.2 eq.) at 0 °C. The mixture was stirred at 0 °C for 10 min and filtered. To this filtrate was added a suspension of NaBH» (1.52 g, 40 mmol, 2 eq.) in water (1.0 mL) at 0 °C. The mixture was stirred for 30 min, added water (3 mL), continued to stir for 2 h, and concentrated to dryness. The crude was purified on silica gel using a mixture of ethylacetate and hexanes as eluent to give (2-bromopyridin-3-yl)methanol (3.4 g, 90%) as a white solid. LRMS (M+H*) m/z 188.0.

Step 2

Π	Imidazole	- ΓΙ
		AL A
Br y	TBSCI	Br^T
(DH		OTBS

• To a mixture of (2-bromopyridin-3-yl)methanol (20.0 g, 106.4 mmol, 1 eq.) and imidazole (14.5 g, 212.8 mmol, 2 eq.) in DMF (50.0 mL) was added TBSC1 (19.2 g, 150.7 mmol, 1.2 eq.) at rt. The mixture was stirred at rt for 1 h and diluted with a mixture of water (100 mL) and EtOAc (300 mL). The organic layer was washed with ΝΗ4θ1(_ωι.) solution and brine, dried over Na2SO4, concentrated, and purified on silica gel using 10% EtOAc/hexanes as eluent to give 2-bromo-3-((tert-butyldimethylsilyloxy)methyl)pyridine (30.1 g, 94%) as a colorless oil. LRMS (M+H⁴) m/z 302.0.

Step 3

ZnfCNfe	- Cl
bCS^ Pd(PPh₃)₄
OTBS	OTBS

A mixture of2-bromo-3-((tert-butyldimethylsilyloxy)methyl)pyridine (30.1 g, 100.0 mmol, 1 eq.) and Zn(CN)2 ( 23.5 g, 200.0 mmol, 2.0 eq.) in DMF (100.0 mL) was purged with N2 for 5 min and added Pd(PPhj)4 (5.78 g, 5.0 mmol, 0.05 eq.). The mixture was heated at 120 °C for 2 h under N2, cooled, filtered, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 3-((tertbutyldimethylsilyloxy)methyl)picolinonitrile (20.4 g, 82%) as a colorless oil. LRMS (M+H⁴) m/z 249.1.

Step 4:

li Ί -	MeMgBr
NcAA	THF
OTBS

Méthylmagnésium bromide (3M/ether, 41.0 mL, 123.4 mmol) was added to a stirred solution of 3-((tert-butyldimethylsilyloxy)methyl)picolinonitrile (20.4 g, 82.25 mmol) in THF (100.0 mL) at -78 °C. The reaction mixture was warm to rt, quenched with aqueous citric acid solution, and extracted with EtOAc (50 mL) twice. The combined organic layers were washed with NaHCOj {_Mt) solution and brine, dried over Na₂SO4, concentrated, and purified on silica gel using a mixture of EtOAc/hexanes as eluent to give l-(3-((tertbutyldimethylsilyloxy)methyI)pyridin-2-yl)ethanone (12.9 g, 59%) as a colorless oil. LRMS (M+H⁴) m/z 266.2.

Step 5:

l-(3-((tert-butyldimethylsilyloxy)methyl)pyridîn-2-yl)ethanone (10.8 g, 40.75 mmol) in dimethoxy-N,N-dimethylmethanamine (15.0 mL) was heated to reflux for 3 days. The mixture was concentrated and used for next step without further purification. LRMS (M+H⁺) m/z 321.1.

Step 6:

Το (E)-1 -(3-((tert-butyldimethylsilyloxy)methyl)pyridin-2-yl)-3(dimethy!amino)prop-2-en-l-one (crude, 1.03 g, 3.22 mmol, 1 eq.) in EtOH (10 mL) was added isopropylhydrazine hydrochloride (430 mg, 3.86 mmol, 1.2 eq.). The mixture was heated at 80 °C for 2 h, cooled, added HCl (6 N, 0.5 mL), and stirred O/N. The mixture was concentrated and diluted with EtOAc (80 mL) and NaHCOj(_Ht) (10 mL) solution. The layers were separated and the aqueous layer was extracted with EtOAc three times. The combined organic layers were dried over Na₂SO4, concentrated, and purified on silica gel using EtOAc as eluent to give (2-(l-isopropyl-lH-pyrazol’5-yl)pyridin-3-yl)methanol (500 mg, 71%) and (2-(l-isopropyl-lH-pyrazol-3-yl)pyridin-5-yl)methanol (55 mg, 25%) as pale yellow oils. Data for 2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methanol: *H NMR (400 MHz, CDCtj) δ 8.67 (dd, J= 4.7,1.5 Hz, 1H), 8.0 (d, J= 7.8 Hz, t H), 7.61 (d, J= 1.8 Hz, 1H), 7.39 (dd, J= 7.8,4.8 Hz, 1H), 6.37 (d, J= 1.8 Hz, 1H), 4.67 (s, 2H), 4.55 (sep, J= 6.6 Hz 1H), 1.98-2.05 (br, 1H), 1.47 (d, J= 6.6 Hz, 6H). LRMS (M+H*) m/z 218.1 Data for (2-(ï-isopropyl-1Hpyrazol-3-yl)pyridin-5-yl)methanol: *H NMR (400 MHz, CDClj) δ 8.62 (dd, J= 4.8,1.6 Hz, 1H), 7.72 (d, J= 7.6 Hz, 1H), 7.55 (d, J= 2.4 Hz, 1H), 7.23 (dd, J= 7.6,4.8 Hz, ï H), 6.99 (dd, 8.0,6.5 Hz, 1H), 6.07 (t, J=7.6 Hz, 1H), 4.67 (d, J= 7.6 Hz, 2H), 4.58 (sep, J= 6.7 Hz, 1H), 1.60 (d, J =6.7 Hz, 1H). LRMS (M+H*) m/z 218.1.

Step 7:

To (2-(l-iospropyl-l H-pyrazol-5-yl)pyridin-3-yl)methanol (560 mg, 2.58 mmol) in DCM ( 10 mL) was added SOC1₂ (3.0 mL) at rt. The reaction mixture was stirred at rt for 4 h - and concentrated to dryness. The crude solid was suspended in toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give 3(chloromethyt)-2-(l -isopropyl-1 H-pyrazot-5-yt)pyridine hydrochloride (700 mg) as an offwhite solid, which was used for next step without further purification.

Step 8:

A mixture of 5-hydroxy-2-methoxybenzaldehyde (395 mg, 2.58 mmol, 1 eq.), 3‘ (chloromethyl)-2-(l -isopropyl-lH-pyrazol-5-yl)pyridine hydrochloride (700 mg, 2.58 mmol, 1 eq.), and K₂CO₃ (1.4 g, 10.32 mmol, 4 eq.) in DMF (10.0 mL) was heated at 70 °C for 2 h. The mixture was cooled, filtered, concentrated, and purified on silica gel using a mixture of

EtOAc and h ex an es as eluent to give 5-((2-(l-isopropyI-lH-pyrazoI-5-yI)pyridin-3yl)methoxy)-2-methoxÿbenzaldehyde (590 mg, 65%) as an off-white solid.

Step 9:

5-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yI)methoxy)-2-methoxybenzaldehyde (980 mg, 2.78 mmol, 1 eq.) in HCl (6 N, 9.2 mL, 20 eq.) solution was frozen at -78 °C. The mixture was lyophilized O/N to give 5-((2-(1-isopropyl-1 H-pyrazol-5-yl)pyri din-3yl)methoxy)-2-methoxybenzaldehyde as a yellow solid.

Example 28. Préparation of2-bromo-3f(2-(l-isopropyldH-pyrazol-5-yl)pyridin~3yl)methoxy)benzaldehyde (Compound 49).

The tîtle compound was prepared according to the procedure described in Example 27.

*H NMR (400 MHz, CDClj) δ 10.46 (s, 2H), 8.77 (d, J= 4.6 Hz, 2H), 8.22 (d, J=

7.9 Hz, 2H), 7.64 (s, 2H), 7.59 (d, 7.8 Hz, 2H), 7.47 (dd, J= 8.0,4.8 Hz, 2H), 7.37 (t,

7.9 Hz, 2H), 7.04 (d, J= 8.1 Hz, 2H), 6.43 (d,J= 1.0 Hz, 2H), 5.11 (s, 4H), 4.67 (sep, 6.6 Hz, 3H), 1.50 (d, 6.6 Hz, 1 IH).

Example 29. Préparation of 2-hydroxy-6-((2-(l-(2,2,2-trifluoroethyl)-lH‘pyrazol-5yl)pyridin-3-y!)methoxy)benzaldehyde (Compound 50).

Step 1 :

70% wt Inwater

HCl (12 N)

To (3,3,3-trifluoroethyI)hydrazine (25 g, 50% wt in water,153.5 mmol, 1 eq.) in a

RB flask (250 mL) was added HCI (12 N, 25.6 mL, 307.0 mmol, 2 eq.). The mixture was concentrated to give (3,3,3-trifluoroethyl)hydrazine dihydrochloride (1.07 g) as a yellow solid. LRMS (M+H) m/z 129.1.

Step 2:

Το (Ε)Λ -(3-((tert-butyldimethylsilyloxy)methyl)pyridîn-2-yl)-3(dimethylamino)prop-2-en-l-one (crude above, 5.91 g, 18.44 mmol, 1 eq.) in EtOH (20 mL) was added (3,3,3-trifluoroethyl)hydrazine dihydrochloride (4.13 g, crude above, 22.13 mmol,

1.2 cq.) at rt. The mixture was heated at 80 °C for 1 h, concentrated, and diluted with EtOAc (50 mL) and NaHCOj(_Mt) solution (10 mL). The layers were separated and aqueous layer was extracted with EtOAc three times. The combined organic layers were dried over NaîSO^, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 3-((tert-butyldimethylsilyloxy)methyl)-2-(l -(3,3,3-trifluoroethyl)-l H-pyrazol-5yl)pyridine (5.90 g; 86% for 2 steps). LRMS (M+H¹) m/z 372.2.

Step 3:

HCl

MeOH

To 3-((tert-butyldimethylsilyloxy)methyl)-2-(l -(3,3,3-trifluoroethyl)-l H-pyrazol-5yl)pyridine (5.91 g, 15.93 mmol) in MeOH (20 mL) was added HCl (4 N, 8.0 mL). The mixture was stirred at rt for 1 h, concentrated, and diluted with EtOAc (50 mL) and NaHCOjfsat) solution (10 mL). The layers were separated and aqueous layer was extracted with EtOAc three times. The combined organic layers were dried over NajSO^ and concentrated to give (2-(1-(3,3,3-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3-yl)methanol (4.1 g, quantitative yield) as colorless oil. ’H NMR (400 MHz, CDCI3) δ 8.54 (dd, J- 4.7,1.5 Hz,

IH), 7.92 (dd, J= 7.9,1.2 Hz, IH), 7.57(d, J= 1.9 Hz, IH), 7.30 (dd, J= 7.8,4.8 Hz, IH),

6.50 (d, J= 1.9 Hz, IH), 5.09(q, J= 8.6 Hz, 2H), 4.63 (s, 2H), 1.76(s, IH). LRMS (M+H⁴) m/z 272.1

Step 4:

SOCI₂

DCM

To (2-(1-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3-yl)methanol (408 mg, 1.59 mmol) in DCM ( 5 mL) was added SOCI₂ (1.5 mL) at rt. The reaction mixture was stirred at rt for 4 h and concentrated to dryness. The crude solid was suspended in toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give 3-(chloromethyl)-2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-y])pyridinehydrochloride (498 mg) as an off-white solid, which was used for next step without further purification.

Step 5:

OH

K₂CO₃. DMF

A mixture of 2,6-dihydroxybenzaldehyde (438 mg, 11.47 mmol, 2 eq.) and K₂COj (2.4 g, 17.22 mmol, 3 eq.) in DMF (150 mL) was stined at rt for 10 min. To this mixture was added 3-(chloromethyl)-2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridinehydrochloride (498 mg, 1.59 mmol, leq.) at rt. The mixture was heated at 50 °C for 2 h, filtered, concentrated and purified on silica gel using a mixture of EtOAc and hexanes as eluent to 2hydroxy-6-((2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (338.4 mg, 56%) as a pale yellow solid. 'H NMR (400 MHz, CDCI₃) δ 11.99 (s, IH), 10.41 (s, 1 H), 8.76 (dd, J = 4.7,1.6Hz, 1 H), 8.01 (dd,J=7.9,1.4 Hz, IH), 7.69(d, J= 1.9Hz,

1H), 7.49-7.39 (m,2H), 6.61 (d, 8.5 Hz, 1H), 6.53 (d, J= 1.9 Hz, 1H), 6.32(d, J= 8.3

Hz, 1H), 5.3O(q, J=8.6 Hz, 2H), 5.17 (s, 2H). LRMS (M+H*) m/z 378.1

Example 30. Préparation of2-hydroxy-6-((2-(l~(3,3,3-trifluoropropyl)~lH-pyrazol-5~ yl)pyridin-3-yl)methoxy)benzaldehyde (Compound 51).

Step 1:

To a mixture of benzyl hydrazinecarboxylate (5.0 g, 30.3 mmol, 1 eq.) and DIEA (15.0 mL, 90.9 mmol, 3 eq.) in DMF (20 mL) was added 3,3,3-trifluoropropyl bromide (10.7 g 60.6 mmol, 2 eq.) at rt. The mixture was heated at 80 °C for 20 h, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes as eluent to benzyl 2-(3,3,3trifluoropropyljhydrazinecarboxylate (4.2 g; 53%) as a white solid. *H NMR (400 MHz, CDC1₃) δ 7.33 - 7.17 (m, 5H), 6.11 (s, 1H), 5.01 (s, 2H), 4.00 (s, 1H), 3.00 (dd, J= 122,7.1 Hz, 2H), 2.17 (qt, J= 10.8,7.3 Hz, 2H). LRMS (M+H*) m/z 263.1

Step 2:

HCl HCl

Tobenzyl 2-(3,3,3-trifluoropropyl)hydrazinecarboxylate (1.7 g, 6.49 mmol, 1 eq.) in a mixture of EtOH (30 mL) were added Pd/C (1.0 g) and HCl (12 N, 2.0 mL). The mixture was charged with H2 (60 psi), stirred at rt for 1 h, fîltered, and concentrated to give (3,3,3trifluoropropyl)hydrazine dihydrochloride (1.07 g) as a yellow solid. LRMS (M+H) m/z 129.1.

Step 3:

To (E)-l-(3-((tert-butyldimethylsilyloxy)methyl)pyridin-2-yl)-3(dimethylamino)prop-2-en-l-one (crude above, 1.73 g, 5.41 mmol, 1 eq.) in EtOH (10 mL) was added (3,3,3-trifluoropropyl)hydrazine dihydrochloride (1.30 g, crude above, 6.49 mmol,

1.2 eq.) at rt. The mixture was heated at 80 °C for 1 h, concentrated, and diluted with EtOAc (50 mL) and NaHCO₃(_Mt) solution (10 mL). The layers were separated and aqueous layer was extracted with EtOAc three times. The combined organic layers were dried over Na₂SO«, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 3 -((tert-butyldimethylsilyloxy)methyl)-2-(l -(3,3,3-trifluoropropyl)-l H-pyrazol-5yl)pyridine ( 1.58 g; 76% for 2 steps). *H NMR (400 MHz, CDClj) δ 8.53 (dd, 4.7,1.6 Hz, IH), 7.96 - 7.88 (m, IH), 7.51 (d, 1.9 Hz, IH), 7.29 (dd, 7.9,4.7 Hz, IH), 6.34 (d,

1.9 Hz, IH), 4.62 (s, 2H), 4.45 -4.33 (m, 2H), 2.82 - 2.61 (m, 2H), 0.85 (s, 8H), -0.00 (s, 5H). LRMS (M+H⁴) m/z 386.2.

Step 4:

To 3-((tert-butyldimethylsilyloxy)methyl)-2-( 1-(3,3,3-trifluoropropyl)-lH-pyrazol5-yl)pyridine (1.58 g, 4.1 mmol) in MeOH (20 mL) was added HCl (4 N, 4.0 mL). The mixture was stirred at rt for 1 h, concentrated, and diluted with EtOAc (50 mL) and NaHCOj(Mi) solution (10 mL). The layers were separated and aqueous layer was extracted with EtOAc three times. The combined organic layers were dried over Na₂SÜ4, and concentrated to give (2-(1-(3,3,3-trifluoropropyl)-lH-pyrazol-5-yl)pyridin-3-yl)methanol (1.1 g, 99%) as colorless oil. *H NMR (400 MHz, CDClj) δ 8.64 (dd, J= 4.7,1.7 Hz, IH), 8.00 (dd, J= 7.9, 1.7 Hz, IH), 7.57 (d, J= 1.9 Hz, IH), 7.38 (dd, 7.9,4.8 Hz, IH), 6.48 (d,

1.9 Hz, 1H), 4.69 (s, 2H), 4.51 - 4.43 (m, 2H), 2.85 - 2.72 (m, 2H), 2.70 (s, 1H). LRMS (M+H⁴) m/z 272.1.

Step 5:

SOCI₂

DCM

To (2-(1-(2,2,2-trifluoropropyl)-lH-pyrazol-5-yl)pyridin-3-yl)methanol (140 mg, 0.52 mmol) in DCM ( 5 mL) was added SOC1₂ (2.0 mL) at rt. The réaction mixture was stirred at rt for 4 h and concentrated to dryness. The crude solid was suspended in toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give 3-(chloromethyl)-2-(l-(2,2,2-trifluoropropyl)-lH-pyrazol-5-yl)pyridine hydrochloride (498 mg) as an off-white solid, which was used for next step without further purification.

Step 6:

OH

K₂CO₃, DMF

A mixture of 2,6-dihydroxybenzaldehyde (144 mg, 1.04 mmol, 2 eq.) and K₂COj (214 mg, 1.56 mmol, 3 eq.) in DMF (20 mL) was stirred at rt for 10 min. To this mixture was added 3-(chloromethyl)-2-(l-(2,2,2-trifluoropropyl)-lH-pyrazol-5-yl)pyridine hydrochloride (168 mg, 0.52 mmol, leq.) at rt. The mixture was heated at 50 °C for 2 h, filtered, concentrated and on RP-HPLC (Gemini 21.2 x 150 mm) using a mixture of CH3CN and water as eluent to give 2-hydroxy-6-((2-(l-(3,3,3-trifluoropropyl)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde (53.5 mg, 26%) as an off-white solid. *H NMR (400 MHz, CDCI3) δ 11.98 (s, 1H), 10.38 (s, 1H), 8.77 (dd,J= 4.7,1.6 Hz, 1H), 8.01 (dd, 7.9, 1.6 Hz, 1H), 7.61 (d, J= 1.9 Hz, 1H), 7.49-7.39 (m, 2H), 6.61 (d, 8.5 Hz, 1H), 6.44 (d, J= 1.9 Hz,

H)» 6.34 (d, J = 8.2 Hz, IH), 5.15 (s, 2H), 4.56 (dd, J= 8.3,6.7 Hz, 2H), 3.02 - 2.72 (m,

2H). LRMS (M+H⁴) m/z 392.1.

Example 31. Préparation of Benzaldéhyde Dérivatives.

Compounds 52-55 were prepared according to the methods described above.

2-F1 uoro-6-((2 -( 1 -(2,2,2-tri fluoroethyl )-1 H-pyrazol -5 -y IJpyridi n-3 yl)methoxy)benzaldehyde (Compound 52). *H NMR (400 MHz, CDCI₃)Ô 10.51 (s, IH), 8.74 (dd, J= 4.7, 1.6 Hz, IH), 8.21 (dd, J= 7.9, 1.6 Hz, IH), 7.70(d, J= 1.9 Hz, IH), 7.547.41 (m, 2H), 6.82 (dd, J= 10.0,8.6 Hz, IH), 6.70 (d, J= 8.5 Hz, IH), 6.56 (d, J= 1.9 Hz, IH), 5.28 (q, J= 8.6 Hz, 2H), 5.20 (s, 2H).

2-Fluoro-6-((2-( 1 -(3,3,3-trifluoropropyl)-1 H-pyrazoI-5-yl)pyridin-3yl)methoxy)benzaldehyde (Compound 53).*H NMR (400 MHz, CDC1₃) Ô 10.50 (s, IH), 8.75 (dd, J= 4.7,1.6 Hz, IH), 8.22 (dd, 7= 7.9,1.6 Hz, IH), 7.62 (d, 7= 1.9 Hz, IH), 7.54-7.42 (m, 2H), 6.83 (dd, J= 10.0,8.7 Hz, IH), 6.73 (d, 7= 8.5 Hz, IH), 6.46 (d, 7= 1.9 Hz, IH), 5.19 (s, 2H), 4.59 - 4.51 (m, 2H), 2.96 - 2.76 (m, 2H).

2-Fluoro-6-((2-(l -isopropyl -1 H-pyrazol-5-yl)pyrid in-3 -y l)methoxy)benzald ehyd e (Compound 54). ’HNMR (400 MHz, CDC1₃) δ 10.41 (s, IH), 8.66 (dd, 7= 4.7,1.6 Hz, IH), 8.13 (dd, J - 7.9,1.4 Hz, IH), 7.55 (d, J= 1.8 Hz, IH), 7.46-7.29 (m, 2H), 6.72 (dd, J= 10.0, 8.7 Hz, IH), 6.59 (d, 7= 8.5 Hz, IH), 6.29 (d, <7=1.8 Hz, IH), 5.03 (s, 2H), 4.56 (sep, J = 6.7 Hz, 1 H), 1.40 (d, J = 6.6 Hz, 6H).

Example 32 Préparation of I-(2-formyl-3-hydroxyphenethyl)piperidine-4-carboxy!ic acid (Compound 55).

OH

Error! Objects cannot bc crcated from editing fîeld codes.

To a solution of 2-bromo-6-hydroxybenzaldehyde (3.8 g, 18.91 mmol, 1 eq.) in a mixture of THF and MeOH (4/1,25 mL) was added NaBH₄ (1.4 g, 37.81 mmol, 1.5 eq.) at rt portion-wise. Upon the completion ofaddition, the mixture was continued to stir at rt for 30 min. The mixture was quenched with HCl (4 N) and extracted with EtOAC twice. The combined organic layer was dried over Na₂SO₄, concentrated, and purified on silica gel using 25% EtOAc/hexanes as eluent to give 3-bromo-2-(hydroxymethyl)phenol (23 g, 60%) as a colorless oil.

Error! Objects cannot be created from cdltlng field codes.

To 3-bromo-2-(hydroxymethyl)phenol (2.3 g, 11.3 mmol, I eq.) in acetone (20.0 mL) were added 2,2-dimethoxypropane (6.0 mL), PTS A (215 mg, 1.13 mmol, 0.1 eq.), and Na₂SÛ4 (5.0 g). The mixture was heated at 40 °C O/N, cooled to rt, and diluted with EtOAc.

The organic layer was washed with NaHCOj(_ML) solution and brine, dried over

Na₂SO4, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes to give 5-bromo-2,2-dÎmethyl-4H-benzo[d][l,3]dioxine (2.1 g, 76%) as a colorless oi. *H NMR (400 MHz, CDClj) δ 7.13 (dd, J= 8.0,1.2 Hz, IH), 7.07 (t, J= 8.0 Hz, IH), 6.81 (dd, 7= 8.0,

1.2 Hz, IH), 4.77 (s, 2H), 1.56 (s, 6H).

Error! Objects cannot be created from editlng field codes.

To a mixture of 5-bromo-2,2-dimethyl-4H-benzo[d][ I,3]dioxine (2.1 g, 8.64 mmol, I eq.), Pd₂(dba)j (400 mg, 0.43 mmol, 0.05 eq.), Q-Phos (460 mg, 0.65 mmol, 0.075 mmol) in THF (100 mL) purged with N₂ for 10 min was added ZnCi(CH₂CO₂Bu) (0.5 M/ether, 35mL, 1738 mmol, 2 eq.). The mixture was heated at 50 °C for 16 h, cooled to rt, added NH₄Cl(sat) solution, and diluted with EtOAc. The organic layer was separated, dried over Na₂SO₄, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes to give tertbutyl 2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)acetate (2.6 g, 80% pure, 87%) as a brown oil. *H NMR (400 MHz, CDClj) δ 7.06 (t, J= 7.9 Hz, 1 H), 6.73 (d, J= 7.4 Hz, IH), 6.68 (d, 7= 8.2 Hz, IH), 4.78 (s, 2H), 1.47 (s, 6H), 136 (s, 9H).

Error! Objects cannot be created from editlng field codes.

To a solution of tert-butyl 2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)acetate (2.6 g, 80% pure, 934 mmol, 1 eq.) in THF (20 mL) were added LiBH₄ (7.0 mL, 14.01 mmol, 1.5 eq.) and MeOH (1.0 mL) at rt. The mixture was stirred at rt for 30 min, added MeOH (20 mL), concentrated to dryness, added MeOH (20 mL) and silica gel, and concentrated to dryness again. The mixture was loaded dîrectly on silica gel for purification using a mixture of EtOAc and hexanes as eluent to give 2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)ethanoI (1.1 g, 71%) as a pale brown oil. 'H NMR (400 MHz, CDClj) δ 7.28 (t, 7= 7.9 Hz, IH), 6.92 (d,/= 7.4 Hz, IH), 6.86 (d, J= 8.2 Hz, IH), 5.02 (s, 2H), 3.99 (q,/= 6.4 Hz, 2H), 2.86 (t, J = 6.6 Hz, 2H), 1.68 (s, 6H), 1.57 (t, J= 5.5 Hz, IH).

Error! Objects cannot be created from editing fïeld codes.

To a solution of2-(2,2-dimethyl-4H-benzo[d][l ,3]dioxin-5-yl)ethanol (400 mg, 1,92 mmol, 1 eq.) in THF (20 mL) were added MsCl (438 mg, 3.84 mmol, 2.0 eq.) and TEA (0.8 mL, 5.76 mmol, 3.0 eq.) at rt. The mixture was stirred at rt for 1 h and diluted with EtOAc. The organic layer was washed with water and brine, dried over Na₂SO4, and concentrated to give 2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)ethyl methanesulfonate (400 mg, crude) as a pale brown oil, which was used for next step without purification.

Error! Objects cannot be creatcd from editing field codes.

To 2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)ethyl methanesulfonate (176 mg,

0.59 mmol, crude above, I eq.) in DMF (1.0 mL) was added ethyl piperidine-4-carboxylate (186 mg, 1.18 mmol, 2.0 eq.) at rt. The mixture was stirred at 60 ®C for 2 h, cooled to rt, and purified on RP-HPLC (Gemini 21.2 mm x 150 mm) using a mixture of CH₃CN and water (0.1% HCOOH) as eluent to give ethyl I-(2-(2,2-dimethyl-4H-benzo[d][I,3]dioxin-5yl)ethyl)pîperidine-4-carboxylate (100 mg, 49% for two steps). *H NMR (400 MHz, CDCI₃) 5 8.45 (s, IH), 7.13 (t,/=7.9 Hz, IH), 6.73 (d, J= 7.9 Hz, 2H), 4.86 (s, 2H), 4.19 (q,/=7.1 Hz, 2H), 3.22 (s, 2H), 3.09-2.95 (m, IH), 2.95 -2.79 (m, 4H), 2.76 (s, IH),2.66-2.48 (m, IH), 2.23 - 1.99 (m, 4H), 1.55 (s, 6H), 1.29 (t, J= 7.1 Hz, 3H). LRMS (M+H*) m/z 348.1.

Error! Objects cannot be created from editing field codes.

To ethyl 1 -(2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)ethyl)piperidine-4carboxylate (100 mg, 0.49 mmol, 1 eq.) in THF (10 mL) were added HCl (6 N, 10 drops) and water (1.0 mL) at rt. The mixture was stirred at 60 °C for 2 h, cooled, and basified with NaHCO₃(sat.) solution. The mixture was filtered and concentrated. The residue wasbring into THF (10 mL) and filtered. The filtrate was concentrated to give ethyl l-(3-hydroxy-2(hydroxymethyl)phenethyI)piperidine-4-carboxylate (85 mg, crude) as a pale brown oil, which was used for next step without purification. LRMS (M+H*) m/z 308.1.

Error! Objects cannot be created from editing field codes.

To ethyl l-(3-hydroxy-2-(hydroxymethyl)phenethyl)piperidine-4-carboxylate (85 mg, crude above) in THF (20.0 mL) was added MnO₂ (500 mg, 5.75 mmol ) at rt. The mixture was stirred at rt for 1 h, filtered, and concentrated to give ethyl l-(2-formyl-382 hydroxyphenethyl)piperidine-4-carboxylate (80 mg, crude) as a pale brown solid, which was used for next step with purification. LRMS (M+H*) m/z 306.1.

Error! Objccts cannot be created from edltlng field codes.

To ethyl l-(2-formyl-3-hydroxyphenethyl)piperidine-4-carboxylate (80 mg, crude above) in THF (5.0 mL) was added NaOH (3 N, 1.0 mL). The mixture was stirred at rt for 2 h and acidified to pH 3-4 using HCl (2 N). The mixture was concentrated and purified on RP-HPLC (Gemini 21.2 mm x 150 mm) using a mixture of CH3CN and water (0.1% HCOOH) as eluent to give l-(2-formyl-3-hydroxyphenethyl)piperidine-4-carboxylic acid (40 mg, 29% for three steps) as a yellow solid. *H NMR (400 MHz, DMSO) 5 10.26 (s, IH),

8.65 (s, 2H), 6.91 (dd,J= 8.7,6.9 Hz, IH), 6.16 (d, J= 7.9 Hz, IH), 5.76 (d, J= 6.7 Hz, IH),

3.01 - 2.89 (m, 4H), 2.50 - 2.36 (m, 2H), 2.03 (t, 10.3 Hz, 2H), 1.92 -1.76 (m, 3H), 1.69

- 1.49 (m, 2H). LRMS (M+H*) m/z 278.4. ’H NMR (400 MHz, DMSO-d6) δ 10.1 (s, IH), 8.55 (s, 2H), 6.75(dd, J = Hz, IH), 6.05 (d, J - Hz, IH), 5.6 (d, J « Hz, ÏH), 2.7 (m, 4H), 2.3 (m, 2H),1.85 (m, 2H),1.7 (m, 3H),1.5 (m, 2H).

IN VITRO TESTING

Example 33. Modulation of Hemoglobin Oxygen ajfinity by Substituted Benzaldehyde Compounds—Assay Procedure.

Oxygen equilibrium curves (OEC) in purified Hemoglobin S (HbS) were measured by the change in p50, the partial pressure of oxygen at which the heme bindîng sites in the 20 HbS sample are 50% saturated with oxygen. HbS was purified by a modified procedure (Antonini and Brunori, 1971; Heomoglobin and Myoglobin in their Reactions with Ligands; North Holland Publishing Company; Amsterdam, London) from blood obtained from homozygous sickle cell patients though the Hemoglobinopathy Center at Children's Hospital Oakland Research Institute (CHORI) with Institutional Review Board approval.

Oxygen equilibrium curves were carried out with a HEMOX analyzer, (TCS Scientific, New Hope, PA). Five hundred pL of250 pM purified HbS were diluted into 4.5 mL of HEMOX buffer (30 mM TES, 130 mM NaCl, 5 mM KC1, pH= 7.4) resulting in a final hemoglobin concentration of25 pM. The compounds were added at the final desired concentrations. The mixture was incubated for 45 min at 37 °C and then transferred to the Hemox sample chamber. The samples were saturated with oxygen by flushing with compressed air for 10 minutes. The samples were then flushed with pure nitrogen and the absorbance of deoxy-Hb was recorded as a function of the solution pO₂. The oxygen equilibrium data was then fit to the Hill Model to obtain values for p50. The deoxygenation curves for both HbS alone (control) and HbS in the presence of compound were collected with the TCS software. The p50 for purified Hbs was typically 13.8 + 1.6. Delta p50 values were obtained from the p50 value for control minus the p50 value for HbS treated with compound divided by the p50 value for the control. A positive delta p50 value corresponds to a left shifted curve and a lower p50 value relative to control, indicating that the compound acts to modulate HbS to increase its affinity for oxygen.

Example 34. Modulation of Hemoglobin Oxygen affinity by Substituted Benzaldehyde Compounds—Assay Results.

The compounds of Table 1 that were where tested in the assay above were ail found 10 to hâve positive delta p50 values. Delta p50% is calculated from [[p50(HbS) - p50(HbS treated with compound)]/p50(HbS)] X 100. Table 2 below lists the delta p50% values where + indicates a delta p50% of between 0 and 29 and ++ indicates a delta p50% of 30 or greater. Unless noted otherwise, the compounds in Table 2 were tested at 30μΜ.

Table 2. delta p50

Compound	delta pSO
1	++
2	+
3	+ (100μΜ)
4	+
5	++
6	+ (100μΜ)
7	++
8	+
9	+
10	++
11	+
12	+ (100μΜ)
13	+
14	+

15	+ (100μΜ)
16 .	+
21	+ (100μΜ)
23	-H-
24	++
25	-H-
33	+ (Ι00μΜ)
34	+
35	+
37	+
38	++(100μΜ)
39	+ (100μΜ)
40	+
41
42
43
44
45

Example 35. Polymerization Assqy.

Polymerization assays are carried out in vitro using purified HBS exchanged into t .8 M potassium phosphate buffer at pH 7.4. Using a slightly modified protocol (Antonini 5 and Brunori, 1971), HbS is purified by the CRO VIRUSYS, from biood obtained from homozygous sickle cell patients through the Hemoglobinopathy Center at Children’s Hospital Oakland Research Institute (CH0R1) with Institutional Review Board approval. Compounds are prepared in 100% DMSO and a desired amount is added to 50 μΜ of purified HBS at a final DMSO concentration of 0.3%. Final potassium phosphate concentration is adjusted to 10 1.8 M using a combination of 2.5 M potassium phosphate stock solution and water at pH 7.4.

The reaction mixture is incubated for an hour at 37 °C and then transferred into a 24-welI plate for deoxygenation in a glove box containing 99.5 % nitrogen and 0.5% oxygen. The 24-well plate is not covered and incubated at 4 °C on a plate cooler inside the glove box for one and a half hours. Fifty pL of the reaction mixture is transferred into a 96-well plate and the absorbance at 700 nm is measured every minute for one hour at 37 °C in a plate reader located inside the glove box. A plot of the absorbance against time is fitted using a Boltzman sigmoidal fit and the delay time (from zéro to time at halfVmax) is measured. To compare and rank compounds, delay times are expressed as percent delay (%DT), which is defined as the différence in delay times for HBS/compound and HBS alone multiplied by 100 and divided by the delay time for HBS alone.

Compounds listed below hâve been tested in the polymerization assay. Activity ranges are defined by the number of dagger (f) symbols indicated. f dénotés activity > 40% but < 80%; ft dénotés activity > 80% but < 120%; ftt dénotés activity > 120% but < 140%; ttft dénotés activity > 160%.

Compound	% delta Delay
42	tt
43	tt
44	t
45	tt
46	t
47	tt
48	t
49	t

Example 36. R/T Assay

A relaxed-to-tense transition assay (“R/T assay”) was used to détermine the ability of substituted benzaldehyde compounds to mantain the high-oxygen affinity relaxed (R) state of hemoglobin under deoxygenated conditions. This ability can be expressed as a “delta R” value (i.e., the change in the time-period of the R state after hemoglobin is treated with a compound, as compared to the period without treatment with the comound). Delta R is the %R to remaining after the compounds treatment compared with no treatment (e.g. if R% without treatment is 8% while with treatment with a target compound is 48% R at 30 μΜ, then %R is 40% for that compound.

A mixture of HbS/A was purified from blood obtained from homozygous sickle cell patients though the Hemoglobinopathy Center at Children's Hospital Oakland Research Institute (CHORI) with Institutional Review Board approval. HbS/A (at a final concentration of 3 μΜ) was incubated for I hr at 37°C in presence or absence of compounds in 50 μΜ potassium phosphate buffer, pH=7.4 and 30 μΜ 2,3 diphosphoglycerate (DPG) in 96 well plates in a final volume of 160 μΐ. Compounds were added at different concentrations (3 μΜ to 100 μΜ final concentrations). Plates were covered with a Mylar film. After incubation was completed the Mylar cover was removed and the plates were placed in a Spectrostar Nano plate reader previously heated at 37°C. Five minutes later, N₂ (flow rate = 20 L/min) was flowed through the spectrophotometer. Spectroscopic measurements (300 nm to 700 nm) were taken every 5 min for 2 hours. Data analysis was performed by using linear régression from the data retrieved for ail wavelengths.

Table 4 below lists the delta R values where + indicates a delta R of between 0 and 30, ++ indicates a delta R of between 30 and 50, and +++ indicates a delta R of 50 or greater. Unless noted otherwise, the compounds in Table 2 were tested at 9 μΜ.

Table 3. delta R

Compound	delta R (%)
5	++
10	++
24	+
25	++
41	+

42	-H-+ (30 pm)
43	+++ (30 pm)
44	+++
45	+++

Example 3 7. Whole Blood Assay

Oxygen Equilibrium Curves (OEC) of whole blood before and after treatment with different concentrations of substituted benzaldehyde compounds were performed as follows using a HEMOX analyzer (TCS Scientific, New Hope, PA). Blood samples from homozygous sickle cell patients were obtained though the Hemoglobinopathy Center at Children's Hospital Oakland Research Institute (CHORI) with Institutional Review Board approval. The hematocrit was adjusted to 20% using autologous plasma and the blood samples were incubated for 1 hour at 37 °C in absence or presence of compounds. 100 pl of these samples were added to 5 mL of Hemox buffer (30 mM TES, 130 mM NaCl, 5 mM KC1, pH= 7.4) at 37 °C and then transferred to the Hemox sample chamber. The samples were saturated with oxygen by flushing with compressed air for 10 minutes. The samples were then flushed with pure nitrogen and the respective absorbances of oxy- and deoxy-Hb are recorded as a fonction ofthe solution pO2. The oxygen equilibrium data were then fitted to the Hill Model to obtain values for p50. The deoxygenation curves for both whole blood alone (control) and whole blood in the presence ofthe compound were collected with the TCS software.

Table 5 below lists the delta p50% values where + indicates a delta p50% of between 0 and 29, ++ indicates a delta p50% of between 30 and 50, and +++ indicates a delta p50% of 50 or greater. The compounds in Table 2 were tested at 1000 pM. A positive delta p50 value corresponds to a left shifted curve and a lower p50 value relative to control, indicating that the compound acts to modulate HbS to increase its affinity for oxygen.

SS

Table 4. delta p50% Values for Whole Blood Assay

Compound	delta p50%
42	+
43	+-H-
44	+
45	+

Example 38. Pharmacokinetîc Study of Compound 43(HCl sait)

J.V.STUDY

Sprague Dawley rats were treated with 7.8 mg/Kg of Compound 43 dîssol ved in

10%DMA:50%PEG: 16%ca vitron. At specified time pojnts 10 uL of whole blood/plasma was removed from rats and treated with490ul pH 3 buffer + 500 uL ACN/IS, then shaken for 1 hour, centrifuged for 10 minutes at 57 rpm at 4C. The supematant was transferred to a filter plate and centriguged at 2000 rpm for 1 minute at 4C. The samples were then analyzed 10 by LC-MS/MS monitoring parent aldéhyde. Concentrations in blood and plasma are shown in Table 5. Key P/K parameters are shown in Table 6.

Table 5

Compound 43 7.8mpk IV in rat
	blood conc (uM)	plasma conc (uM)
time (min)	A	B	C	A	B	C
0	BLLOQ	BLLOQ	BLLOQ	BLLOQ	BLLOQ	BLLOQ
5	259	246	281	7.56	8.68	7.44
15	287	341	285	8.38	8.42	7.16
30	283	333	292	no sample	8.66	7.1
60	256	203	285	6.12	7.52	7.22
120	263	274	280	3.92	6.02	5.22
240	248	225	259	3.72	5.24	5.88
480	118	136	22.9	2.06	2.66	3.15

1440

81.1

85

70.8

1.07

138

Table 6

Compound 43 7.8mpk IV in rat
		Blood	Plasma
tl/2 beta	min	749.0	619.1
CL	m!/min/kg	0.08	4.45
Vss	L/kg	0.09	4.11
AUCIast	min*umol/L	215846.3	4114.8

ORAL STUDY

SD Rats were treated by gavage with 44 mg/kg and 100 mg/kg dissolved in

10%DMA:90% PEG. At specified time points blood was taken and worked up as described above in the IV Study. Key Parameters are shown in Table 7.

Table 7

Compound 43 :2 PO in rats
Blood	Plasma
				ratio			ratio
dose	mg/kg	44	100	2.27	44	100	2.27
Tmax	min	320.00	720.00		200.00	680.00
Cmax	umol/L	381.33	1096.67	2.88	14.79	44.53	3.01
AUCIast	min*umol/L	395638.27	1384101.11	3.50	12517.54	52836.17	4.22

AU patents, patent applications, publications and présentations referred to herein are incorporated by reference in their entirety. Any conflict between any reference cited herein and the teaching of this spécification is to be resolved in favor of the latter. Similarly, any conflict between an art-recognized définition of a Word or phrase and a définition of the word or phrase as provided in this spécification is to be resolved in favor of the latter.

Claims

WHAT IS CLAIMED IS:

1. A compound of Formula (I):

η (I) or a tautomer or pharmaceutically acceptable sait thereof, wherein Q is selected from the group consisting of aryl, heteroaryl, and heterocycloalkyl, each optionally substituted with one to three R“;

Y is O or CR^laR^Ib, where R¹* is H or halo and R^,b is selected from the group consisting of H, halo, and OH;

X is selected from the group consisting of O, >CH(CH2)nR⁸, and C(R⁹)₂ where n is 0 or 1, R* is OH, and R⁹ is independently H or halo; or Y-X taken together is -NHC(O)- or C(O)NH-;

R², R³, R⁴, and R⁵ are independently selected from the group consisting of hydrogen, halo, R^b, OR^d, -O(CH2)xOR^d, -O(CH2)_xNR^dR^d, OC(O)R^e, SR^d, CN, NO2, CO2R^d, CONR^dR^d, C(O)R^d, OC(O)NR^dR^d, NR^dR^d, NR^dC(O)R^e, NR^dC(O)2R^e, NR^dC(O)NR^dR^d, S(O)R^e, S(O)2R^e, NR^dS(O)2R^e, S(O)2NR^dR^d, and N3, where z is 0,1,2,3,4,5, or 6; or R⁵ is -(CH2)pR^Sa where p is 0 or 1 and R^5a is OH;

R⁶ and R⁷ together form oxo or an aldéhyde protecting group, or R⁶ together with R^lb, R⁸, or R^s forms a cyclic ether where one of R^lb, R⁸, or R^Sa is O, R⁶ is a bond, and R⁷ is selected from the group consisting of OH, Cj^alkoxy, and haloCj^alkoxy;

each R is independently selected from the group consisting of halo, oxo, R^b, OR^d,

O(CH₂)_uOR^d, O(CH2)uNR^dR^d, O(CH2)_üNR^dC(O)R^e, O(CH2)uNR^dC(O)2R^e, O(CH2)üNR^dS(O)2R^e, NH2, -(CH₂)_kOC(O)R^e, -(CH2)kSR^d, CN, NO2, -(CH₂)_kCO2(C|. jalkyl)OH, -(CH2)_kCO₂(C_l_₈alkyl)(heteroaryl)C(O)(C₁.₈alkyl), -(C^HCOX -(CH₂)kCONR^dR^d, -(CH2)kNR^dC(O)R^e, -(CH2)_kNR^dC(O)2R^e, -(CH2)kC(O)R^d, -(CH2)kOC(O)NR^dR^d, -NR^d(CH2)uOR^d, -NR^d(CH2)uNR^dR^d, -NR^d(CH2)uNR^dC(O)R^e, -NR^d(CH2)uNR^dC(O)2R^e, -NR^d(CH2)uNR^dS(O)2R^e, -(CH2)kNR^dC(O)R^e, -(CH2)_lcNR^dC(O)2R^d,

-(CH₂)_kNR^dC(O)NR^dR^d, -(CH2)kS(O)R^e, -(CH2)_kS(O)₂R^e, -(CH2)kNR^dS(O)2R^e, -(CH2)kS(O)2NR^dR^d, Nj, -(CH2)_karyl optionally substituted with one to three R^c, -NR^d(CH2)karyl optionally substituted with one to three R^c, -(CH2)_kheteroaryl optionally substituted with one to three R®, -NR^d(CH2)kheteroaryl optionally substituted with one to three R^c, -(CH2)_kheterocycloalkyl optionally substituted with one to three R^c, and -NR^d(CH₂)_kheterocycloalkyl optionally substituted with one to three R^c where k is 0,1,2,3, 4,5, or 6 and u is 1,2,3,4,5, or 6;

each R^b is independently selected from the group consisting of Ci-galkyl, C^alkenyl, and C₂.g alkynyl, each optionally independently substituted with one to three halo, OR^d, or NR^dR^d;

each R^c is independently selected from the group consisting of halo, Ct.galkyl, haloCi. galkyl, C2.galkenyl, haloC2^ alkenyl, C2-galkynyl, haloC2-8alkynyl, (CH2)mOR^f, OC(O)R^g, SR^f, CN, NO2, CO₂R^f, CONR^fR^f, C(O)R^f, OC(O)NR^fR^f, (CH2)mNR^fR^f, NR^fC(O)R⁽, NR^fC(O)2R^B, NR^fC(O)NR^fR^f, S(O)R⁸, S(O)2R^e, NR^fS(O)2R⁸, S(O)₂NR^fR^f, Nj, heteroaryl optionally substituted with one to three R^h, and heterocycloalkyl optionally substituted with one to three R^h where m is selected from the group consisting of 0,1,2,3,4,5, and 6;

each R^b is independently selected from the group consisting of halo, Ci^alkyl, haloCi. galkyl, OR^J, OC(O)R, SR^j, NO2, CO2R^j, CONR^JR^j, C(O)R^J, OC(O)NR^JR^J, NR^JR^J, NR^jC(O)R’, NR^jC(O)2R', NR'CCOJNRW, S(O)R', S(O)₂R', NR^jS(O)₂R', and S(O)₂NR^JR^J;

R^d, R^f, and R^J are each independently selected from the group consisting of hydrogen, Cj-8 alkyl, haloCi-galkyl, C₂.g alkenyl, haloC₂.galkenyl, C₂.g alkynyl, and haloC₂.galkynyl; and

R^e, R^g, and R’ are each independently selected from the group consisting of Ci-galkyl, haloCi-galkyl, C₂.g alkenyl, haloC₂.galkenyl, C₂.g alkynyl, and haloC₂^alkynyl;

provided that X and Y are not both O;

provided that when X is O, R^lb is not OH;

provided that when Y is O, and n is 0, R⁸ is not OH; and provided that when R⁶ and R⁷ together are oxo, Y is CH₂, X is O or CH₂, and R* is H, halo, OH, CHO, or OCHj, then Q is V or W;

V is selected from the group consisting of

W is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, and pyridine-44O F*N λ'-Ν N'N N'N , s ^N4 ^N4 /4 π · w ,· yl, , , and ? , wherein W is optionally substituted with one to three R* or is substituted with one to three R when W is pyridin-2-yl, pyridin-3-yl, or pyridine-4-yI, and wherein the wavy line signifies the point of attachment to Y, provided that when V is optionally substituted with one R^a, then at least one of R², R³, R⁴, and R⁵ is OR^d; and provided that when V is
2. A compound according to claim 1, wherein:

YisOorCHj;

X is O or CH_2:

Q is selected from the group consisting of:

iii) imidazopyridinyl, methylimidazopyridinyl, indazolyl, pyrrolopyridinyl, pyrrolopyrazinyl, pyrazolopyridinyl, pyrazolopyrazinyl, and quinolinyl, each of which is optionally substituted with one to three R¹; wherein

4 ♦ J *

R, R , R , and R, are independently selected from the group consisting of hydrogen, halo, R^b, OR^d, O(CH2)2OR^d, O(CH2)₂NR^dR^d, OC(O)R^c, SR^d, CN, NO2, CO2R^d, CONR^dR^d, C(O)R^d, OC(O)NR^dR^d, NR^dR^d, NR^dC(O)R^e, NR^dC(O)2R^e, NR^dC(O)NR^dR^d, S(O)R^e, S(O)₂R^e, NR^dS(O)2R^e, S(O)2NR^dR^d, and Nj where z is 1,2, or 3; and iv) pyridinyl and piperidinyl, each of which is optionally substituted with one to three R¹; wherein

R², R³, and R⁴ are independently selected from the group consisting of hydrogen, halo, R^b, OR^d, O(CH2)2OR^d, O(CH2)₂NR^dR^d, OC(O)R^e, SR^d, CN, NO2, CO2R^d, CONR^dR^d, C(O)R^d, OC(O)NR^dR^d, NR^dR^d, NR^dC(O)R^e, NR^dC(O)2R^e, NR^dC(O)NR^dR^d, S(O)R^e, S(O)₂R^e, NR^dS(O)2R^e, S(O)2NR^dR^d, and N₃ where z is 1,2, or 3; and

R^s is selected from the group consisting of halo and OR^d;

R⁶ and R⁷ together form oxo or an aldéhyde protecting group;

5 each R¹ is independently selected from the group consisting of halo, oxo, R^b,

OR^d, O(CH₂)_uOR^d, O(CH2)uNR^dR^d, O(CH2)_uNR^dC(O)R^e, O(CH₂)_uNR^dC(O)2R^e, O(CH2)_uNR^dS(O)2R^e, NH2, -(CH₂)_kOC(O)R^e, -(CH2)kSR^d, CN, NO2) -(CH₂)_kCO₂(Ci_ galkyl)OH,-(CH₂)_kCO₂(C₁.₈alkyl)(heteroaryl)C(O)(C^alkyl),-(CH₂)_kCO₂R^d, -(CH₂)_kCONR^dR^d, -(CH2)kNR^dC(O)R^e, -(CH2)_kNR^dC(O)₂R^e, -(CH₂)_kC(O)R^d,

10 -(CH₂)_kOC(O)NR^dR^d, -NR^d(CH2)uOR^d, -NR^d(CH2)_uNR^dR^d, -NR^d(CH2)uNR^dC(O)R‘, -NR^d(CH2)_uNR^dC(O)2R^e, -NR^d(CH2)_uNR^dS(O)2R^e, -(CH2)_kNR^dC(O)R^e, -(CH2)kNR^dC(O)2R^d, -(CH₂)_kNR^dC(O)NR^dR^d, -(CH2)kS(O)R^e, -(CH2)_kS(O)₂R^e, -(CH₂XNR^dS(OhR^e, -C(O)(CH2)kNR^dS(O)2R*, -(CH₂)_kC(O)NR^dS(O)2R*, -(CH2)kS(O)2NR^dR^d N3, -(CH₂)_karyl optionally substituted with one to three R^c, -NR^d(CH₂)_karyl optionally substituted with one to

15 three R^c, -(CH₂)_kheteroaryl optionally substituted with one to three R^e, -NR^d(CH2)kheteroaryl optionally substituted with one to three R^c, -(CH2)_kheterocycloalkyl optionally substituted with one to three R^c, and -NR^d(CH₂)_kheterocycloalkyl optionally substituted with one to three R^c wherekisO, 1,2,3,4,5, or 6 and u is 1,2,3,4,5, or 6;

each R^b is independently selected from the group consisting of Ci-galkyl, C₂. 20 galkenyl, and C₂.ealkynyl, each optionally independently substituted wîth one to three halo, OR^d,orNR^dR^d;

each R^e is independently selected from the group consisting of halo, Cj.8alkyl, haloC|_8alkyl, C2.8alkenyl, haloC2-salkenyl, C2_galkynyl, haloC2_8alkynyl, (CH2)mOR^f, OC(O)R^g, SR^f, CN, NOz, (CH2)_mCO₂R^f, CONR^fR^f, C(O)R^r, OC(O)NR^rR^f, (CH2)fflNR^fR^f, 25 NR^fC(O)R^g, NR^fC(O)2R^g, NR^fC(O)NR^rR^f, S(O)R^g, S(O)2R^g, NR^rS(O)2R^g, S(O)2NR^fR^f, N3, (R^mSiQ-galkyl, heteroaryl optionally substituted with one to three R^h, cycloalkyl optionally substituted with one to three R^h, and heterocycloalkyl optionally substituted with one to three R^h where m is selected from the group consisting of 0, 1,2,3,4,5, and 6;

each R^h is independently selected from the group consisting ofhalo, Cijalkyl, 30 haloC|.8alkyl, OR^j, OC(O)R, SR^j, NO2, CQzR¹, CONR^jR^j, C(O)R^j, OC(O)NR^jR^j, NR^jR^j, NR^jC(O)R', NR^jC(O)2R‘, NR^jC(O)NR^jR^j, S(O)R*, S(O)2R‘, NR^jS(O)₂R', and S(O)₂NR^jR^j;

R^d, R^f, and R^j are each independently selected from the group consisting of hydrogen, Cj.g alkyl, haloC|_galkyl, C₂.g alkenyl, haloC₂^alkenyl, C₂.g alkynyl, and haloC₂. _galkynyl; and

R^e, R®, and R* are each independently selected from the group consisting of C|. galkyl, haloCi^alkyl, C₂^ alkenyl, haloC₂^alkenyl, C₂.g alkynyl, and haloC₂. galkynyj.
3. A compound according to claim 1, wherein:

Y is CH_2; and X is CH₂.
4. A compound according to claim 2, or a tautomer or pharmaceutically acceptable sait thereof, wherein Q is selected from the group consisting of imidazo[l,5a]pyridin-8-yl, imidazo[l,5-a]pyridin-6-yl, imidazo[l,5-a]pyridin-5-yl, imidazo[l,2a]pyridin-8-yl, imidazo[l,2-a]pyridin-7-yl, imidazo[l,2-a]pyridin-6-yi, imidazo[l,2aJpyridin-5-yl, imidazo[l,2-a]pyridin-3-yl, 8-methylimidazo[l,2-a]pyridin-2-yl, indazol-4-yl, pyrrolo[2,3-b]pyridin-4-yl, pyrrolo[ 1,2-a]pyrazin-6-yl, pyrrolof 1,2-a]pyrazin-4-yl, pyrazolo[3,4-b]pyridin-4-yl, pyrazolo[l,5-a]pyrazin-3-yl, and quinolin-5-yl, each of which is optionally substituted with one to three R*.
5. A compound according to claim 4, or a tautomer or pharmaceutically acceptable sait thereof, wherein R² is selected from the group consisting of H and OR^d;

R³ is selected from the group consisting of H, CN, halo, and OR^d;

R⁴ is selected from the group consisting of H, CN, and OR^d: and

R^s is H.
6. A compound according to claim 5, or a tautomer or pharmaceutically acceptable sait thereof, wherein R⁴ is methoxy.
7. A compound according to claim 3, or a tautomer or pharmaceutically acceptable sait thereof, wherein Q is selected from the group consisting of pyridine-3-yl and piperidin-l-yl.
8. A compound according to claim 7, or a tautomer or pharmaceutically acceptable sait thereof, wherein R^s is selected from the group consisting of hydroxy and fluoro.
9. A compound according to any of the preceeding cJaïms, or a tautomer or pharmaceutically acceptable sait thereof, wherein R⁶ and R⁷ together form oxo.
10. A compound according to claim 1 selected from the group consisting of:

2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)-5-methoxybenzaldehyde,

4- formyl-3-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)benzonitrile,

2-(imidazo[l,2-a]pyridin-8-ylmethoxy)-4-methoxÿbenzaJdehyde,

2-(imidazo[ 1,2-a]pyridin-6-ylmethoxy)-5-methoxybenzaldehyde,

2-(imidazo[l,5-a]pyridÎn-8-ylmethoxy)-4-methoxybenzaldehyde, 2-(i midazo [ 1,5-a]pyri di n- 8-ylmetho xy)-5-m ethoxÿbenzal dehyde, 2-(imidazo[l,2-a]pyridin-7-yJmethoxy)-5-methoxybenzaldehyde, 2-(imidazo[ J ,2-a]pyridin-3-ylmethoxy)-5-methoxybenzaldehyde,

5- methoxy-2-(quinolin-5-ylmethoxy)benzaldehyde, 5-bromo-2-(imidazo[l ,2-a]pyndin-8-ylmethoxy)benzaldehyde, 4-chloro-2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)benzaldehyde, 2-(imidazo[ 1,2-a] pyrid in-8-ylmethoxy)benzald ehyde,

4- fluoro-2-(imidazo[l,2-a]pyridin-8-ylmethoxy)benzaldehyde, 2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)-3-methoxÿbenzaldehyde, 2-(imîdazo[ 1,2-a]pyridin-8-ylmethoxy)-5-methylbenzaldehyde, ·

5- methoxy-2-(pyrrolo[l,2-a]pyrazin-4-ylmethoxy)benzaldehyde, 2-(imidazo[l,5-a]pyridin-6-ylmethoxy)-4-methoxybenzaJdehyde,

2- (imidazo[ 1,5-a]pyridin-5-ylmethoxy)-5-methoxybenzaldehyde,

3- formyl-4-(imidazo[ 1 ₍5-a]pyridin-5-ylmethoxy)benzonitrile,

2-((lH-pynOlo[2,3-b]pyridin-4-yl)methoxy)-5-methoxybenzaldehyde,

5-ethyl-2-(imidazo[l,2-a]pyridin-8-ylmethoxy)benzaldehyde,

5-methoxy-2-((l-methyl-lH-indazol-4-yl)methoxy)benzaldehyde,

5-methoxy-2-((8-methylimidazo[l,2-a]pyridin-2-yl)methoxy)benzaldehyde,

2-(( 1 H-indazol-4-yl)methoxy)-5-methoxybenzaldehyde,

2-((1 H-pynOlo[2,3-b]pyridin-4-yl)methoxy)-5-methoxybenzaldehyde,

S-formyM-fimidazon^-aJpyridin-S-ylmethoxyJbenzonïtrile,

5- methoxy-2-(pynolo[ 1,2-a]pyrazin-6-ylmethoxy)benzaldehyde,

6- ((2-formyl-4-methoxyphenoxy)methyl)pyrrolo[ 1,2-a]pyrazine-7- carbonitrile,

6-((2-formyl-4-methoxyphenoxy)methyl)pynolo[ 1,2-a]pyrazine-7carboxamide,

2-((1 H-pyrazolo[3,4-b]pyridin-4-yl)methoxy)-5-methoxybenzaldehyde,

5-methoxy-2-(pyrazolo[ 1,5-a]pyrazin-3-y1methoxy)benzaldehyde,

5-methoxy-2-(pyrrolo[ 1,2-a]pyrazin-6-ylmethoxy)benzaldehyde,

2- (imidazo[ 1,5-a]pyridin-6-ylmethoxy)-5-methoxybenzaldehyde,

3- formyl-4-(imidazo[l,2-a]pyridÎn-8-y1methoxy)benzonitrile,

3-(imidazo[l,2-a]pyridin-8-ylmethyl)-l,3-dihydroisobenzofuran-l-ol,

2-(imidazo[ 1,2-a]pyridin-5-ylmethoxy)-5-methoxybenzaldehyde,

N-(2-formyl-4-methoxyphenyl)imidazo[ 1,2-a]pyridine-8-carboxamide,

N-(2-formylphenyl)imidazo[l,2-a]pyridine-8-carboxamide,

2-formyl-N-(imidazo[ 1,2-a]pyridin-8-yl)benzamide,

2-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-y1)methoxy)-5methoxybenzal dehyd e,

2-hydroxy-6-((2-( 1 -isopropyl-1 H-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde

2-((3-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde,

2-((4-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde,

2-hydroxy-6-((2-( 1 -(2,2,2-trifluoroethyl)-l H-pyrazol-5-yl)pyridin-3yl )methoxy)b enzaldehy d e,

2-hydroxy-6-((2-(l -(3,3,3-trifluoropropyl)-l H-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-fluoro-6-((2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-fluoro-6-((2-(l-(3,3,3-trifluoropropyl)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-fluoro-6-((2-(l-isopropyl-lH-pyrazol-5-yI)pyridin-3yl)methoxy)benzaldehyde, and

1- (2-formyl-3-hydroxyphenethyl)piperidine-4-carboxylic acid or a tautomer or pharmaceutically acceptable sait thereof.
11. A compound according to claim 1 seiected from the group consisting of:

2- (imidazo[ 1,2-a]pyridin-8-ylmethoxy)-5-methoxybenzaldehyde,

2-(imidazo[ 1,5-a]pyridin-8-ylmethoxy)-5-methoxybenzaldehyde,

5-methoxy-2-(quinolin-5-ylmethoxy)benzaldehyde,

5-methoxy-2-((l -methyl-1 H-indazol-4-yl)methoxy)benzaldehyde,

5-methoxy-2-((8-methylimïdazo[l,2-a]pyridin-2-yl)methoxy)benzaldehyde,

2-((1 H-indazol-4-yl)methoxy)-5-methoxybenzaldehyde,

2-((2-( 1 -isopropyl-1 H-pyrazol-5-yl)pyridin-3-yl)methoxy)-5metho xyb enzal d ehyde,

2-hydroxy-6-((2-( 1 -isopropyl-1 H-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-((3-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde,

2-((4-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde,

2-hydroxy-6-((2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-hydroxy-6-((2-(l-(3,3,3-trifluoropropyl)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-fluoro-6-((2-( 1 -(2,2,2-trifluoroethyl)-1 H-pyra2ol-5-yl)pyridm-3yl)methoxy)benzaldehyde,

2-fluoro-6-((2-(l-(3,3,3-trifluoropropyl)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)b enzaldehyde,

2-fluoro-6-((2-(l-isopropyl-lH-pyrazoI-5-yl)pyridin-3y!)methoxy)benzaldehyde, and l-(2-formyl-3-hydroxyphenethyl)piperidine-4-carboxylic acid, or a tautomer or pharmaceutically acceptable sait thereof.

•
12. A pharmaceutical composition comprising a compound of any of the preceding daims or a tautomer or pharmaceutically acceptable sait thereof.
13. A compound of any of the preceding daims or a tautomer or pharmaceutically acceptable sait for use in increasing tissue oxygénation.
14. A compound of any of the preceding daims or a tautomer or pharmaceutically acceptable sait thereof for use in treating a condition associated with oxygen deficiency.
15. The compound of daim 14, wherein the condition is selected from the group consisting of sickle cell disease, cancer, a pulmonary disorder, stroke, high altitude

100 sickness, an ulcer, a pressure sore, Alzheimer’s disease, acute respiratory disease syndrome, and a wound
16. The compound of any of daims 13-15, wherein the compound is selected from the group consisting of:

2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)-5-methoxybenza!dehyde,

4- formyl-3-(imidazo[l,2-a]pyridin-8-ylmethoxy)benzonitrile,

2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)-4-methoxybenzaldehyde,

2-(imidazo[ 1,2-a]pyridin-6-ylmethoxy)-5-methoxybenzaldehyde,

2-(imidazo[ 1,2-a]pyridin-2-ylmethoxy)-5-methoxÿbenzaldehyde,

2-(imidazo[ 1,5-a]pyridin-8-ylmethoxy)-4-methoxÿbenzaldehyde,

2-(imidazo[ 1,5-a]pyridin-8-ylmethoxy)-5-methoxÿbenza!dehyde,

2-(imidazo[l,2-a]pyridin-7-ylmethoxy)-5-methoxybenzaldehyde,

2-(imidazo[ 1,2-a]pyridin-3-ylmethoxy)-5-methoxybenza!dehyde,

5- methoxy-2-(quino!in-5-ylmethoxy)benza!dehyde,

5-bromo-2-(imidazo[l,2-a]pyridin-8-ylmethoxy)benza!dehyde,

4-chloro-2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)benzaldehyde,

2-(imidazo[ 1,2-a]pyridin-8-y!methoxy)benzaldehyde,

4- fluoro-2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)benzaldehyde,

2-(imidazo[l,2-a]pyridin-8-ylmethoxy)-3-methoxybenzaldehyde,

2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)-5-methylbenza]dehyde,

5- methoxy-2-(pyrroIo[ 1,2-a]pyrazin-4-ylmethoxy)benzaldehyde,

2-(imidazo[ 1,5-a]pyridin-6-ylmethoxy)-4-methoxybenzaldehyde,

2- (imidazo[ 1,5-a]pyridin-5-ylmethoxy)-5-methoxybenzaldehyde,

3- formyl-4-(imidazo[ 1,5-a]pyridin-5-ylmethoxy)benzonitrile,

101 carbonitrüe, carboxamide,

2-((lH-pyrrolo[2,3-b]pyridin-4-yl)methoxy)-5-methoxybenzaldehyde,

5-ethyl-2-(imidazo[l,2-a]pyridin-8-ylmethoxy)benzaldehyde,

5-methoxy-2-(( 1 -methyl-1 H-indazol-4-yl)methoxy)benzaldehyde₍

5-methoxy-2-((8-methylimidazo[ 1,2-a]pyridin-2-yl)methoxy)benzaldehyde,

2-((lH-indazo!-4-yI)methoxy)-5-methoxybenzaldehyde_>

2- ((lH-pyrro!o[2_>3-b]pyridin-4-yl)methoxy)-5-methoxybenza!dehyde,

3- formyl-4-(imidazo[ 1,2-a]pyridin-8-yImethoxy)benzonitri!e,

5- methoxy-2-(pyrTolo[l,2-a]pyrazin-6-yImethoxy)benza!dehyde,

6- ((2-formyI-4-methoxyphenoxy)methy!)pyrroIo[ 1,2-a]pyrazine-7-

6-((2-formyl-4-methoxyphenoxy)methy!)pyTTOlo[ 1,2-a]pyrazine-7-

2-((lH-pyrazo!o[3,4-b]pyridin-4-yl)methoxy)-5-methoxybenzaIdehyde,

5-methoxy-2-(pyrazolo[ 1,5-a]pyrazin-3-y!methoxy)benzaldehyde„ .5-methoxy-2-(pyrroIo[l,2-a]pyrazin-6-y!methoxy)benzaIdehyde,

2- (imidazo[ 1,5-a]pyridin-6-ylmethoxy)-5-methoxybenza!dehyde,

3- formy!-4-(imidazo[ 1,2-a]pyridin-8-y!methoxy)benzonitrile,

3- (imidazo[ 1,2-a]pyridïn-8-ylmethyl)-l,3-dihydroisobenzofuran-l -ol,

2-(imidazo[ I ^-ajpyridin-S-ylmethoxyJ-S-methoxybenzaldehyde,

N-(2-formy!-4-methoxyphenyl)imÎdazo[l,2-a]pyridine-8-carboxamide,

N-(2-formy!phenyl)imidazo[ 1,2-a]pyridine-8-carboxamide,

2-formyI-N-(imidazo[l,2-a]pyridin-8-yl)benzamide_t

5-methoxy-2-(pyridin-3-ylmethoxy)benzaIdehyde,

4- ((2-formyl-3-hydroxyphenoxy)methyl)benzoicacid,

102

2-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)-5methoxybenzaldehyde,

2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzal dehyd e,

2-((3-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde,

2-((4-(2H-tetrazoI-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde, methyl 4-((2-formylphenoxy)methyl)benzoate,

4-((2-formylphenoxy)methyl)benzoic acid, methyl 3-((2-formylphenoxy)methyl)benzoate,

2-hydroxy-6-((2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-hydroxy-6-((2-( 1 -(3,3,3-trifluoropropyl)-l H-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-fluoro-6-((2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-fluo ro-6-((2-( 1 -(3,3,3-trifluoropropyl)-1 H-pyrazol-5-yl)pyridin-3yl)methoxy)benzal dehyd e,

2-fluoro-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde, and

1- (2-formyl-3-hydroxyphenethyl)piperidine-4-carboxylic acid or a tautomer or pharmaceutically acceptable sait thereof.
17. The compound of any of daims 13-15, wherein the compound is selected from the group consisting of:

2- (imidazo[ 1,2-a]pyridin-8-yImethoxy)-5-methoxybenzaldehyde,

4-formyl-3-(imïdazo[ 1,2-a]pyridin-8-ylmethoxy)benzonitrile,

2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)-4-methoxybenzaldehyde,

103

2-(imidazo[ 1,2-a]pyridin-6-ylmethoxy)-5-methoxybenzaldehyde,

2-(imidazo[l,2-a]pyridin-2-ylmethoxy)-5-methoxybenzaldehyde, 2-(imidazo[ 1,5-a]pyridin-8-ylmethoxy)-4-methoxybenzaldehyde,

2-(imidazo[l,5-a]pyridin-8-ylmethoxy)-5-methoxybenzaIdehyde,

2-(imidazo[ 1,2-a]pyridin-7-ylmethoxy)-5-methoxybenzaldehyde,

2-(imi dazo [ 1,2-a] pyri din-3 -ylmethoxy)-5-m ethoxybenzaldehyd e,

5-methoxy-2-(quinolin-5-ylmethoxy)benzaldehyde,

5-bromo-2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)benzaldehyde,

4-chloro-2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)benzaldehyde, 2-(imidazo[ 1,2-a]pyridin-8-ylmethoxy)benzaldehyde,

4- fluoro-2-(imidazo[l,2-a]pyridin-8-ylmethoxy)benzaldehyde,

2- (i mi dazo[ 1,2-a] pyri din- 8 -ylmethoxy)-3 -methoxybenzal dehy de,

2-(imidazo[ 1 _t2-a]pyridin-8-ylmethoxy)-5-methylbenzaldehyde, . 5-methoxy-2-(pyrrolo[ 1,2-a]pyrazin-4-ylmethoxy)benzaldehyde,

2-(imidazo[ 1,5-a]pyridin-6-ylmethoxy)-4-methoxybenzaldehyd e,

2- (imidazo[l,5-a]pyridin-5-ylmethoxy)-5-methoxÿbenzaldehyde,

3- formyl-4-(imidazo[ 1,5-a]pyridin-5-ylmethoxy)benzonitrile,

2-((1 H-pyrroIo[2,3-b]pyridin-4-yl)methoxy)-5-methoxybenzaldehyde,

5- ethyl-2-(imidazo[l,2-a]pyridin-8-ylmethoxy)benzaIdehyde,

5-methoxy-2-(( 1 -methyl-1 H-indazol-4-yl)methoxy)benzaldehyde,

5-methoxy-2-((8-methylimidazo[l,2-a]pyridin-2-yl)methoxy)benzaldehyde,

2- (( 1 H-indazol-4-yl)methoxy)-5-methoxybenzaldehyde,

2- ((lH-pyrrolo[2,3-b]pyridin-4-yl)methoxy)-5-methoxÿbenzaldehyde,

3- formyl-4-(imidazo[l,2-a]pyridin-8-ylmethoxy)benzonitrile,

104

5- methoxy-2-(pyrrolo[ 1,2-a]pyrazin-6-ylmethoxy)benzaldehyde,

6- ((2-formyl-4-methoxyphenoxy)methyl)pyrrolo[ 1,2-a]pyrazine-7- carbonîtrile,

6-((2-formyl-4-methoxyphenoxy)methyl)pyrrolo[l,2-a]pyrazine-7- carboxamide,

2-(( 1 H-pyrazolo[3,4-b]pyridin-4-yl)methoxy)-5-methoxybenzaldehyde,

5-methoxy-2-(pyrazolo[l,5-a]pyrazin-3-ylmethoxy)benzaldehyde,

5-methoxy-2-(pyrrolo[l,2-a]pyrazin-6-ylmethoxy)benzaldehyde,

2- (imi dazo[ 1,5-a] pyridin-6-ylmethoxy)- 5-methoxyb enzal dehyde,

3- formyl-4-(imïdazo[ 1,2-a]pyridin-8-ylmethoxy)benzonitrile,

3- (imidazo[l,2-a]pyridm-8-ylmethyl)-l,3-dihydroisobenzofùran-l-ol,

2-(imidazo[l,2-a]pyridin-5-ylmethoxy)-5-methoxybenzaldehyde,

N-(2-formyl-4-methoxyphenyl)imidazo[l_f2-a]pyridine-8-carboxamîde,

N-(2-formylphenyl)imidazo[l,2-a]pyridine-8-carboxamide,

2-formyI-N-(imidazo[ 1,2-a]pyridin-8-yI)benzamide,

5-methoxy-2-(pyridin-3-ylmethoxy)benzaldehyde,

4- ((2-fbrmyl-3-hydroxyphenoxy)methyi)benzoic acid,

2-((2-(1 -isopropyl-1 H-pyrazol-5-yl)pyridin-3-yi)methoxy)-5methoxybenzaldehyde,

2-hydroxy-6-((2-(1 -isopropyl-l H-pyrazol-5-yI)pyridin-3yl)methoxy)benzaldehyde,

2-((3-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde,

2-((4-(2H-tetrazol-5-yl)benzyI)oxy)-6-hydroxybenzaldehyde, methyl 4-((2-formyIphenoxy)methyl)benzoate,

4-((2-formylphenoxy)methyl)benzoic acid,

105

5 methyl 3-((2-formylphenoxy)methyl)benzoate,

2-hydroxy-6-((2-(l-(2,2^-trifluoroethyl)-IH-pyrazol-5-yl)pyridin-3yl)methoxy)benza!dehyde,

2-hydroxy-6-((2-(l-(3,3,3-trifluoropropyl)-lH-pyrazol-5-y!)pyridin-3yl )methoxy)benzal dehyde,

10 2-fluoro-6-((2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3y!)m ethoxy)benzal deh yde,

2-fluoro-6-((2-(l-(3,3,3-trifluoropropy!)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,

2-fluoro-6-((2’(l’îsopropyl-lH-pyrazo1-5-y1)pyridin-315 yl)methoxy)benzaldehyde, and l-(2-formy!-3-hydroxyphenethy!)piperidîne-4-carboxylic acid or a tautomer or pharmaceutically acceptable sait thereof.